Invitae (NVTAQ) 10-Q 8 May 20 2020 Q1 Quarterly report Financial data

Cover Page

Cover Page - shares	3 Months Ended
	Mar. 31, 2020	May 01, 2020
Cover [Abstract]
Entity Registrant Name	Invitae Corp
Document Type	10-Q
Document Period End Date	Mar. 31, 2020
Current Fiscal Year End Date	--12-31
Document Quarterly Report	true
Document Transition Report	false
Title of 12(b) Security	Common Stock, $0.0001 par value per share
Trading Symbol	NVTA
Security Exchange Name	NYSE
Entity Incorporation, State or Country Code	DE
Entity Central Index Key	0001501134
Entity File Number	001-36847
Amendment Flag	false
Entity Current Reporting Status	Yes
Entity Interactive Data Current	Yes
Entity Filer Category	Large Accelerated Filer
Entity Small Business	false
Entity Emerging Growth Company	false
Entity Shell Company	false
Entity Common Stock, Shares Outstanding		125,012,944
Document Fiscal Year Focus	2020
Document Fiscal Period Focus	Q1
Entity Tax Identification Number	27-1701898
Entity Address, Address Line One	1400 16th Street
Entity Address, City or Town	San Francisco
Entity Address, State or Province	CA
Entity Address, Postal Zip Code	94103
City Area Code	415
Local Phone Number	374-7782

Condensed Consolidated Balance

Condensed Consolidated Balance Sheets - USD ($) $ in Thousands	Mar. 31, 2020	Dec. 31, 2019
Current assets:
Cash and cash equivalents	$ 90,220	$ 151,389
Marketable securities	204,388	240,436
Accounts receivable	37,734	32,541
Prepaid expenses and other current assets	25,085	18,032
Total current assets	357,427	442,398
Property and equipment, net	41,085	37,747
Operating lease assets	37,588	36,640
Restricted cash	6,343	6,183
Intangible assets, net	163,378	125,175
Goodwill	177,432	126,777
Other assets	7,635	6,681
Total assets	790,888	781,601
Current liabilities:
Accounts payable	25,982	10,321
Accrued liabilities	88,793	64,814
Operating lease obligations	5,125	4,870
Finance lease obligations	1,370	1,855
Total current liabilities	121,270	81,860
Operating lease obligations, net of current portion	42,767	42,191
Finance lease obligations, net of current portion	1,019	1,155
Convertible senior notes, net	272,387	268,755
Deferred tax liability	10,250	0
Other long-term liabilities	17,062	8,000
Total liabilities	464,755	401,961
Commitments and contingencies (Note 8)
Stockholders’ equity:
Common stock	10	10
Accumulated other comprehensive income (loss)	1,294	(9)
Additional paid-in capital	1,182,033	1,138,316
Accumulated deficit	(857,204)	(758,677)
Total stockholders’ equity	326,133	379,640
Total liabilities and stockholders’ equity	$ 790,888	$ 781,601

Condensed Consolidated Statemen

Condensed Consolidated Statements of Operations - USD ($) shares in Thousands, $ in Thousands	3 Months Ended
	Mar. 31, 2020	Mar. 31, 2019
Revenue:
Total revenue	$ 64,248	$ 40,553
Cost of revenue	40,422	21,254
Research and development	55,668	17,994
Selling and marketing	42,120	24,193
General and administrative	23,822	13,319
Loss from operations	(97,784)	(36,207)
Other income, net	4,708	638
Interest expense	(5,451)	(2,108)
Net loss	$ (98,527)	$ (37,677)
Net loss per share, basic and diluted (in dollars per share)	$ (0.99)	$ (0.47)
Shares used in computing net loss per share, basic and diluted	99,632	79,369
Test revenue
Revenue:
Total revenue	$ 63,078	$ 39,619
Other revenue
Revenue:
Total revenue	$ 1,170	$ 934

Condensed Consolidated Statem_2

Condensed Consolidated Statements of Comprehensive Loss - USD ($) $ in Thousands	3 Months Ended
	Mar. 31, 2020	Mar. 31, 2019
Statement of Comprehensive Income [Abstract]
Net loss	$ (98,527)	$ (37,677)
Other comprehensive income:
Unrealized income on available-for-sale marketable securities, net of tax	1,303	13
Comprehensive loss	$ (97,224)	$ (37,664)

Condensed Consolidated Statem_3

Condensed Consolidated Statements of Stockholders' Equity - USD ($) $ in Thousands	Total	Common stock:	Accumulated other comprehensive income (loss):	Additional paid-in capital:	Accumulated deficit:	Restatement adjustmentAdditional paid-in capital:
Balance, beginning of period at Dec. 31, 2018		$ 8	$ (5)	$ 678,548	$ (516,712)
Increase (Decrease) in Stockholders' Equity [Roll Forward]
Common stock issued		1		184,490
Unrealized income on available-for-sale marketable securities, net of tax			13
Common stock issued on exercise of stock options, net				2,019
Common stock issued pursuant to exercises of warrants				88
Common stock issued or issuable pursuant to business combinations				416
Stock-based compensation expense				5,223
Net loss	$ (37,677)				(37,677)
Balance, end of period at Mar. 31, 2019	316,412	9	8	870,784	(554,389)
Balance, beginning of period at Dec. 31, 2019	379,640	10	(9)	1,138,316	(758,677)
Balance, beginning of period (Immaterial error related to classification of Indemnification from acquisition) at Dec. 31, 2019						$ (10,387)
Increase (Decrease) in Stockholders' Equity [Roll Forward]
Unrealized income on available-for-sale marketable securities, net of tax			1,303
Common stock issued on exercise of stock options, net				1,145
Common stock issued pursuant to exercises of warrants				27
Common stock issued or issuable pursuant to business combinations				42,453
Stock-based compensation expense				10,479
Net loss	(98,527)				(98,527)
Balance, end of period at Mar. 31, 2020	$ 326,133	$ 10	$ 1,294	$ 1,182,033	$ (857,204)

Condensed Consolidated Statem_4

Condensed Consolidated Statements of Cash Flows - USD ($) $ in Thousands	3 Months Ended
	Mar. 31, 2020	Mar. 31, 2019
Cash flows from operating activities:
Net loss	$ (98,527)	$ (37,677)
Adjustments to reconcile net loss to net cash used in operating activities:
Depreciation and amortization	6,056	3,286
Stock-based compensation	29,278	5,223
Amortization of debt discount and issuance costs	3,632	0
Remeasurements of liabilities associated with business combinations	(3,367)	(130)
Other	(659)	388
Changes in operating assets and liabilities, net of businesses acquired:
Accounts receivable	(5,167)	2,596
Prepaid expenses and other current assets	(7,053)	(3,365)
Other assets	602	1,019
Accounts payable	13,085	(307)
Accrued expenses and other liabilities	(240)	601
Net cash used in operating activities	(62,360)	(28,366)
Cash flows from investing activities:
Purchases of marketable securities	0	(20,781)
Proceeds from sales of marketable securities	12,532	0
Proceeds from maturities of marketable securities	24,965	6,000
Acquisition of businesses, net of cash acquired	(32,199)	0
Purchases of property and equipment	(3,831)	(2,764)
Other	(667)	0
Net cash provided by (used in) investing activities	800	(17,545)
Cash flows from financing activities:
Proceeds from public offerings of common stock, net	0	184,490
Proceeds from issuance of common stock, net	1,172	2,107
Finance lease principal payments	(621)	(477)
Net cash provided by financing activities	551	186,120
Net increase (decrease) in cash, cash equivalents and restricted cash	(61,009)	140,209
Cash, cash equivalents and restricted cash at beginning of period	157,572	118,164
Cash, cash equivalents and restricted cash at end of period	96,563	258,373
Supplemental cash flow information of non-cash investing and financing activities:
Purchases of property and equipment in accounts payable and accrued liabilities	3,956	2,389
Common stock issued for acquisition of businesses	42,453	416
Consideration payable for acquisition of businesses	5,773	0
Operating lease assets obtained in exchange for lease obligations, net	$ 2,131	$ 1,617

Organization and description of

Organization and description of business	3 Months Ended
	Mar. 31, 2020
Organization, Consolidation and Presentation of Financial Statements [Abstract]
Organization and description of business	Organization and description of business Invitae Corporation ("Invitae," “the Company," "we," "us," and "our") was incorporated in the State of Delaware on January 13, 2010, as Locus Development, Inc. and changed its name to Invitae Corporation in 2012. We utilize an integrated portfolio of laboratory processes, software tools and informatics capabilities to process DNA-containing samples, analyze information about patient-specific genetic variation and generate test reports for clinicians and patients. Our headquarters and main production facility is located in San Francisco, California. We currently have more than 20,000 genes in production and provide a variety of diagnostic tests that can be used in multiple indications. We offer genetic testing across multiple clinical areas, including hereditary cancer, cardiology, neurology, pediatrics, metabolic conditions and rare diseases. To augment our offering and realize our mission, we have acquired multiple assets including four businesses in 2017 which expanded our suite of genome management offerings and facilitated our entry into prenatal and perinatal genetic testing, and three businesses in 2019 to advance our Non-Invasive Prenatal Screen ("NIPS") offering at lower costs, further enhance our genetic variant interpretation and expand our ability to scale and deliver genetic information. In 2020, we acquired Orbicule BV operating under the name "Diploid" ("Diploid") to enable us to quickly diagnose genetic disorders using artificial intelligence, as well as Genelex Solutions, LLC ("Genelex") and YouScript Incorporated ("YouScript") to bring pharmacogenetic testing and integrated clinical decision support to Invitae. Invitae operates in one segment. Basis of presentation The accompanying unaudited condensed consolidated financial statements have been prepared in accordance with U.S. generally accepted accounting principles (“U.S. GAAP”) for interim financial information and in accordance with the instructions to Form 10-Q and Rule 10-01 of Regulation S-X. Accordingly, they do not include all of the information and footnotes required by generally accepted accounting principles for complete financial statements. The unaudited interim condensed consolidated financial statements have been prepared on the same basis as the annual financial statements. In the opinion of management, the accompanying unaudited condensed consolidated financial statements reflect all adjustments (consisting only of normal recurring adjustments) considered necessary for a fair presentation. The information included in this Quarterly Report on Form 10-Q should be read in conjunction with the audited financial statements and notes thereto included in our Annual Report on Form 10-K for the year ended December 31, 2019 . The results for the three months ended March 31, 2020

Summary of significant accounti

Summary of significant accounting policies	3 Months Ended
	Mar. 31, 2020
Accounting Policies [Abstract]
Summary of significant accounting policies	Summary of significant accounting policies Principles of consolidation Our unaudited condensed consolidated financial statements include our accounts and the accounts of our wholly-owned subsidiaries. All intercompany balances and transactions have been eliminated in consolidation. Use of estimates The preparation of financial statements in conformity with U.S. GAAP requires management to make judgments, estimates and assumptions that affect the reported amounts of assets and liabilities and disclosure of contingent liabilities as of the date of the financial statements and the reported amounts of revenue and expenses during the reporting period. We base these estimates on current facts, historical and anticipated results, trends and various other assumptions that we believe are reasonable under the circumstances, including assumptions as to future events. Actual results could differ materially from those judgments, estimates and assumptions. We evaluate our estimates on an ongoing basis. Concentrations of credit risk and other risks and uncertainties Financial instruments that potentially subject us to a concentration of credit risk consist of cash, cash equivalents, marketable securities and accounts receivable. Our cash and cash equivalents are held by financial institutions in the United States. Such deposits may exceed federally insured limits. Significant customers are those that represent 10% or more of our total revenue presented on the consolidated statements of operations. Our revenue from significant customers as a percentage of our total revenue was as follows: Three Months Ended March 31, 2020 2019 Medicare 21 % 22 % Cash, cash equivalents and restricted cash The following table provides a reconciliation of cash, cash equivalents and restricted cash reported within the consolidated balance sheets that sum to the total of the same amounts shown in the statements of cash flows (in thousands): March 31, December 31, Cash and cash equivalents $ 90,220 $ 151,389 Restricted cash 6,343 6,183 Total cash, cash equivalents and restricted cash $ 96,563 $ 157,572 Inventory We maintain test reagents and other consumables primarily used in sample collection kits which are valued at the lower of cost or net realizable value. Cost is determined using actual costs on a first-in, first-out basis. Our inventory was $13.3 million and $6.6 million as of March 31, 2020 and December 31, 2019 , respectively, and was recorded in prepaid expenses and other current assets on our consolidated balance sheets. Fair value of financial instruments Our financial instruments consist principally of cash and cash equivalents, marketable securities, accounts payable, accrued liabilities, finance leases and liabilities associated with business combinations. The carrying amounts of certain of these financial instruments, including cash and cash equivalents, accounts receivable, accounts payable and accrued and other current liabilities approximate their current fair value due to the relatively short-term nature of these accounts. Based on borrowing rates available to us, the carrying value of our finance leases approximate their fair values. Liabilities associated with business combinations are recorded at their estimated fair value. Prior period reclassifications We have reclassified certain amounts in prior periods to conform with current presentation. Immaterial correction of an error We determined the historical classification of certain acquisition-related obligations as equity and the subsequent measurement of such obligations was inappropriate and instead should have been classified as liabilities and subsequently measured at fair value with changes recognized in other income, net. We determined that the impact of the error to previously issued financial statements was not material and have corrected the immaterial error in the current period financial statements. The impact of this correction was an increase to other long-term liabilities of $10.1 million , a corresponding decrease to additional paid-in capital of $10.4 million and an increase to other income, net of $0.3 million . Recent accounting pronouncements We evaluate all Accounting Standards Updates (“ASUs”) issued by the Financial Accounting Standards Board ("FASB") for consideration of their applicability. ASUs not included in the disclosures in this report were assessed and determined to be either not applicable or are not expected to have a material impact on our consolidated financial statements. Recently adopted accounting pronouncements In June 2016, FASB issued ASU 2016-13, Financial Instruments-Credit Losses (Topic 326), which requires measurement and recognition of expected credit losses for financial assets. This guidance became effective for us beginning in the first quarter of 2020 and was adopted using a modified retrospective approach, with certain exceptions. The adoption of Topic 326 did not have a material impact on our consolidated financial statements as credit losses are not expected to be significant. As part of our adoption of Topic 326, we assess our accounts receivables for expected credit losses at each reporting period by disaggregating by payer type and further by portfolios of customers with similar characteristics, such as customer type and geographic location. We then review each portfolio for expected credit losses based on historical payment trends as well as forward looking data and current economic trends. If a credit loss is determined, we record a reduction to our accounts receivable balance with a corresponding general and administrative expense.

Revenue, accounts receivable an

Revenue, accounts receivable and deferred revenue	3 Months Ended
	Mar. 31, 2020
Revenue from Contract with Customer [Abstract]
Revenue, accounts receivable and deferred revenue	Revenue, accounts receivable and deferred revenue Test revenue is generated from sales of diagnostic tests to three groups of customers: institutions, such as hospitals, clinics and partners; patients who pay directly; and patients’ insurance carriers. Amounts billed and collected, and the timing of collections, vary based on whether the payer is an institution, a patient or an insurance carrier. Other revenue consists principally of revenue recognized under collaboration and genome network agreements and is accounted for under the provisions provided in ASC 606, Revenue from Contracts with Customers . The following table includes our revenues as disaggregated by payer category (in thousands): Three Months Ended March 31, 2020 2019 Test revenue: Institutions $ 13,497 $ 8,154 Patient - direct 5,791 3,741 Patient - insurance 43,790 27,724 Total test revenue 63,078 39,619 Other revenue 1,170 934 Total revenue $ 64,248 $ 40,553 We recognize revenue related to billings based on estimates of the amount that will ultimately be realized. Cash collections for certain diagnostic tests delivered may differ from rates originally estimated. As a result of new information, we updated our estimate of the amounts to be recognized for previously delivered tests which resulted in the following increases to revenue and decreases to our loss from operations and basic and diluted net loss per share (in millions, except per share amounts): Three Months Ended March 31, 2020 2019 Revenue $ 1.4 $ 0.4 Loss from operations $ (1.4 ) $ (0.4 ) Net loss per share, basic and diluted $ (0.01 ) $ (0.01 ) Influence of COVID-19 Our test volumes began decreasing significantly in the second half of March 2020 as a result of COVID-19 and related limitations and priorities across the healthcare system. While it is too early to predict the full impact COVID-19 will have on our business, we expect it to have a material impact on our financial results for at least the next quarter and for the foreseeable future. Approximately 8% of our workforce as of March 31, 2020 was impacted by a reduction in force in April 2020 in an initiative to manage costs and cash burn that resulted in one-time costs in the second quarter of 2020 of $3.8 million . In addition, effective May 2020, we have reduced the salaries of our named executive officers by approximately 20% . On March 27, 2020, the Coronavirus Aid, Relief, and Economic Security Act ("CARES Act") was signed into law which was a stimulus bill intended to bolster the economy, among other things, and provide assistance to qualifying businesses and individuals. The CARES Act included an infusion of funds into the healthcare system, and in April 2020, we received $3.8 million as a part of this initiative. This payment will be recognized in our consolidated statement of operations in April 2020. At this time, we are not certain of the availability, extent or impact of any future relief provided under the CARES Act. Accounts receivable The majority of our accounts receivable represents amounts billed to institutions (e.g., hospitals, clinics, partners) and estimated amounts to be collected from third-party insurance payers for diagnostic test revenue recognized. Also included are amounts due under the terms of collaboration and genome network agreements for diagnostic testing and data aggregation reporting services provided and proprietary platform access rights transferred. Deferred revenue We record deferred revenue when cash payments are received or due in advance of our performance related to one or more performance obligations. The amounts deferred to date primarily consist of prepayments related to our consumer direct channel as well as consideration received pertaining to the estimated exercise of certain re-requisition rights. In order to comply with loss contract rules, our re-requisition rights revenue deferral is no less than the estimated cost of fulfilling related obligations. We recognize revenue related to re-requisition rights as the rights are exercised or expire unexercised, which is generally within 90 days of initial deferral.

Business combinations

Business combinations	3 Months Ended
	Mar. 31, 2020
Business Combinations [Abstract]
Business combinations	Business combinations Singular Bio In June 2019, we acquired 100% of the fully diluted equity of Singular Bio Inc. ("Singular Bio"), a privately held company developing single molecule detection technology, for approximately $57.3 million , comprised of $53.9 million in the form of 2.5 million shares of our common stock and the remainder in cash. Our purchase price allocation for the acquisition is preliminary and subject to revision as additional information about fair value of assets and liabilities becomes available, primarily related to our deferred tax liability assumed in connection with the acquisition as the short period tax return has not yet been filed. Additional information that existed as of the acquisition date but at the time was unknown to us may become known to us during the remainder of the measurement period, a period not to exceed 12 months from the acquisition date. We granted approximately $90.0 million of RSUs under our 2015 Stock Incentive Plan as inducement awards to new employees who joined Invitae in connection with our acquisition of Singular Bio. $45.0 million of the RSUs are time-based and vest in three equal installments in December 2019, June 2020, and December 2020, subject to the employee's continued service with us ("Time-based RSUs") and $45.0 million of the RSUs are performance-based RSUs ("PRSUs") that vest upon the achievement of certain performance conditions over a period of approximately 12 months from the date of acquisition, subject to the employee's continued service with us. Since the number of awards granted is based on a 30-day volume weighted-average share price with a fixed dollar value, these Time-based RSUs and PRSUs are liability-classified and the fair value will be estimated at each reporting period based on the number of shares that are expected to be issued at each reporting date and our closing stock price, which combined are categorized as Level 3 inputs. Therefore, fair value of the RSUs and PRSUs and the number of shares to be issued will not be fixed until the awards vest. During the three months ended March 31, 2020 , we recorded research and development stock-based compensation expense of $7.6 million related to the Time-based RSUs and $11.2 million related to the PRSUs based on our evaluations of the probability of achieving performance conditions. As of March 31, 2020 , the Time-based RSUs and PRSUs had a total fair value of $43.1 million and $44.4 million , respectively, based on a total estimated issuance of 6.2 million shares and expectation of the achievement of the performance conditions. As of March 31, 2020 , 0.8 million of the Time-based RSUs had vested and none of these PRSUs had vested. Jungla In July 2019, we acquired 100% of the equity interest of Jungla Inc. ("Jungla"), a privately held company developing a platform for molecular evidence testing in genes, for approximately $59.0 million , comprised of $44.9 million in the form of shares of our common stock and the remainder in cash. We agreed to pay a portion of the cash and issue approximately 0.2 million shares of our common stock after a 12-month period, subject to a hold back to satisfy indemnification obligations that may arise. We may be required to pay contingent consideration based on achievement of post-closing development milestones. As of the acquisition date, the fair value of this contingent consideration was $10.7 million including cash and common stock. The milestones are expected to be completed within two years . The material factors that may impact the fair value of the contingent consideration, and therefore, this liability, are the probabilities and timing of achieving the related milestones and the discount rate we used to estimate the fair value. Significant changes in any of the probabilities of success would result in a significant change in the fair value, which will be estimated at each reporting date with changes reflected as a general and administrative expense. Our purchase price allocation for the acquisition is preliminary and subject to revision as additional information about fair value of assets and liabilities becomes available, primarily related to our deferred tax liability assumed in connection with the acquisition as the short period tax return has not yet been filed. Additional information that existed as of the acquisition date but at the time was unknown to us may become known to us during the remainder of the measurement period, a period not to exceed 12 months from the acquisition date. As of March 31, 2020 , we had a stock payable liability of $2.7 million which represents the hold-back obligation to issue 0.2 million shares subject to indemnification claims that may arise in connection with our acquisition of Jungla. This liability is adjusted at each reporting period based on the fair value of our common stock, which is a Level 3 input, with the change recorded in other income, net. Clear Genetics In November 2019, we acquired 100% of the equity interest of Clear Genetics Inc. ("Clear Genetics"), a developer of software for providing genetic services at scale, for approximately $50.1 million . Of the cash and stock purchase price consideration issued, $0.2 million of cash and approximately 0.4 million shares of our common stock are subject to a 12-month hold back to satisfy indemnification obligations that may arise. Our purchase price allocation for the acquisition is preliminary and subject to revision as additional information about fair value of assets and liabilities becomes available, primarily related to our deferred tax liability assumed in connection with the acquisition as the short period tax return has not yet been filed. Additional information that existed as of the acquisition date but at the time was unknown to us may become known to us during the remainder of the measurement period, a period not to exceed 12 months from the acquisition date. As of March 31, 2020 , we had a stock payable liability of $5.7 million which represents the hold-back obligation to issue 0.4 million shares subject to indemnification claims that may arise in connection with our acquisition of Clear Genetics. This liability is adjusted at each reporting period based on the fair value of our common stock, which is a Level 3 input, with the change recorded in other income, net. Diploid In March 2020, we acquired 100% of the equity interest of Diploid, a developer of artificial intelligence software capable of diagnosing genetic disorders using sequencing data and patient information, for approximately $82.3 million in cash and shares of our common stock. Of the stock purchase price consideration issued, approximately 0.4 million shares are subject to a hold-back to satisfy indemnification obligations that may arise. We included the financial results of Diploid in our consolidated financial statements from the acquisition date, which were not material for the three months ended March 31, 2020 . The following table summarizes the purchase price recorded as a part of the acquisition of Diploid (in thousands): Purchase Price Cash transferred $ 32,323 Hold-back consideration - common stock 7,538 Common stock transferred 42,453 Total $ 82,314 Assets acquired and liabilities assumed are recorded based on valuations derived from estimated fair value assessments and assumptions used by us. While we believe that our estimates and assumptions underlying the valuations are reasonable, different estimates and assumptions could result in different valuations assigned to the individual assets acquired and liabilities assumed, and the resulting amount of goodwill. The following table summarizes the fair values of assets acquired and liabilities assumed through our acquisition of Diploid at the date of acquisition (in thousands): Cash $ 124 Accounts receivable 26 Developed technology 41,789 Total identifiable assets acquired 41,939 Accounts payable (30 ) Deferred tax liability (10,250 ) Net identifiable assets acquired 31,659 Goodwill 50,655 Total purchase price $ 82,314 Based on the guidance provided in ASC 805, Business Combinations , we accounted for the acquisition of Diploid as a business combination in which we determined that 1) Diploid was a business which combines inputs and processes to create outputs, and 2) substantially all of the fair value of gross assets acquired was not concentrated in a single identifiable asset or group of similar identifiable assets. Our purchase price allocation for the acquisition is preliminary and subject to revision as additional information about fair value of assets and liabilities becomes available, primarily related to our deferred tax liability assumed in connection with the acquisition. Additional information that existed as of the acquisition date but at the time was unknown to us may become known to us during the remainder of the measurement period, a period not to exceed 12 months from the acquisition date. We measured the identifiable assets and liabilities assumed at their acquisition date fair values separately from goodwill. The intangible asset acquired is developed technology related to Diploid's artificial intelligence technology platform. The fair value of the developed technology was estimated using an income approach with an estimated useful life of nine years . As of the acquisition date, we recorded a stock payable liability of $7.5 million to represent the hold-back obligation to issue 0.4 million shares subject to indemnification claims that may arise. This liability is adjusted at each reporting period based on the fair value of our common stock, which is a Level 3 input. As of March 31, 2020 , the value of this liability was $5.8 million with the change recorded in other income, net. Goodwill represents the excess of the purchase price over the fair value of the net tangible and intangible assets acquired. The acquisition of Diploid resulted in the recognition of $50.7 million of goodwill which we believe relates primarily to expansion of the acquired technology to apply to new areas of genetic testing. Goodwill created as a result of the acquisition of Diploid is not deductible for tax purposes. As part of our acquisition of Diploid, we intend to grant approximately $5.0 million

Goodwill and intangible assets

Goodwill and intangible assets	3 Months Ended
	Mar. 31, 2020
Goodwill and Intangible Assets Disclosure [Abstract]
Goodwill and intangible assets	Goodwill and intangible assets Goodwill The changes in the carrying amounts of goodwill were as follows (in thousands): Balance as of December 31, 2019 $ 126,777 Goodwill acquired - Diploid 50,655 Balance as of March 31, 2020 $ 177,432 Intangible assets The following table presents details of our intangible assets (in thousands): March 31, 2020 December 31, 2019 Cost Accumulated Net Weighted-Average Cost Accumulated Net Weighted-Average Customer relationships $ 23,763 $ (5,841 ) $ 17,922 10.0 $ 23,763 $ (5,141 ) $ 18,622 10.0 Developed technology 126,185 (11,291 ) 114,894 8.7 84,396 (8,476 ) 75,920 8.6 Non-compete agreement 286 (186 ) 100 5.0 286 (172 ) 114 5.0 Trade name 576 (519 ) 57 2.7 576 (480 ) 96 2.7 Patent licensing agreement 496 (79 ) 417 15.0 496 (70 ) 426 15.0 Favorable leases 247 (247 ) — 2.2 247 (238 ) 9 2.2 In-process research and development 29,988 — 29,988 n/a 29,988 — 29,988 n/a $ 181,541 $ (18,163 ) $ 163,378 8.9 $ 139,752 $ (14,577 ) $ 125,175 8.9 Acquisition-related intangibles included in the above table are finite-lived, other than in-process research and development which has an indefinite life, and are carried at cost less accumulated amortization. Customer relationships are being amortized on an accelerated basis, in proportion to estimated cash flows. All other finite-lived acquisition-related intangibles are being amortized on a straight-line basis over their estimated lives, which approximates the pattern in which the economic benefits of the intangible assets are realized. Amortization expense was $3.6 million and $1.3 million for the three months ended March 31, 2020 and 2019 , respectively. Amortization expense is recorded to cost of revenue, research and development, sales and marketing and general and administrative expense. The following table summarizes our estimated future amortization expense of intangible assets with finite lives as of March 31, 2020 (in thousands): 2020 (remainder of year) $ 13,568 2021 18,426 2022 16,721 2023 15,708 2024 15,430 Thereafter 53,537 Total estimated future amortization expense $ 133,390

Balance sheet components

Balance sheet components	3 Months Ended
	Mar. 31, 2020
Balance Sheet Related Disclosures [Abstract]
Balance sheet components	Balance sheet components Property and equipment, net Property and equipment consisted of the following (in thousands): March 31, 2020 December 31, 2019 Leasehold improvements $ 21,422 $ 18,352 Laboratory equipment 26,983 24,873 Computer equipment 6,476 5,995 Software 2,611 2,611 Furniture and fixtures 1,277 1,198 Automobiles 58 58 Construction-in-progress 10,239 10,795 Total property and equipment, gross 69,066 63,882 Accumulated depreciation and amortization (27,981 ) (26,135 ) Total property and equipment, net $ 41,085 $ 37,747 Depreciation expense was $2.0 million and $1.6 million for the three months ended March 31, 2020 and 2019 , respectively. Accrued liabilities Accrued liabilities consisted of the following (in thousands): March 31, 2020 December 31, 2019 Accrued compensation and related expenses $ 18,927 $ 16,440 Compensation and other liabilities associated with business combinations 55,789 30,560 Deferred revenue 1,460 1,429 Other 12,617 16,385 Total accrued liabilities $ 88,793 $ 64,814

Fair value measurements

Fair value measurements	3 Months Ended
	Mar. 31, 2020
Fair Value Disclosures [Abstract]
Fair value measurements	Fair value measurements Financial assets and liabilities are recorded at fair value. Fair value is defined as the price that would be received to sell an asset or paid to transfer a liability (an exit price) in an orderly transaction between market participants at the reporting date. The authoritative guidance establishes a three-level valuation hierarchy that prioritizes the inputs to valuation techniques used to measure fair value based upon whether such inputs are observable or unobservable. Observable inputs reflect market data obtained from independent sources, while unobservable inputs reflect market assumptions made by the reporting entity. The three-level hierarchy for the inputs to valuation techniques is summarized as follows: Level 1—Observable inputs such as quoted prices (unadjusted) for identical instruments in active markets. Level 2—Observable inputs such as quoted prices for similar instruments in active markets, quoted prices for identical or similar instruments in markets that are not active, or model-derived valuations whose significant inputs are observable. Level 3—Unobservable inputs that reflect the reporting entity’s own assumptions. The following tables set forth the fair value of our consolidated financial instruments that were measured at fair value on a recurring basis (in thousands): March 31, 2020 Amortized Cost Unrealized Estimated Fair Value Gains Losses Level 1 Level 2 Level 3 Financial assets: Money market funds $ 32,653 $ — $ — $ 32,653 $ 32,653 $ — $ — Certificates of deposit 300 — — 300 — 300 — U.S. treasury notes 137,937 1,157 — 139,094 139,094 — — U.S. government agency securities 64,857 137 — 64,994 — 64,994 — Total financial assets $ 235,747 $ 1,294 $ — $ 237,041 $ 171,747 $ 65,294 $ — Financial liabilities: Stock payable liability $ 14,362 $ — $ — $ 14,362 Contingent consideration 11,200 — — 11,200 Total financial liabilities $ 25,562 $ — $ — $ 25,562 March 31, 2020 Reported as: Cash equivalents $ 26,310 Restricted cash 6,343 Marketable securities 204,388 Total cash equivalents, restricted cash, and marketable securities $ 237,041 Accrued liabilities $ 8,500 Other long-term liabilities $ 17,062 December 31, 2019 Amortized Cost Unrealized Estimated Fair Value Gains Losses Level 1 Level 2 Level 3 Financial assets: Money market funds $ 39,396 $ — $ — $ 39,396 $ 39,396 $ — $ — Certificates of deposit 300 — — 300 — 300 — U.S. treasury notes 150,627 — (15 ) 150,612 150,612 — — U.S. government agency securities 193,302 6 — 193,308 — 193,308 — Total financial assets $ 383,625 $ 6 $ (15 ) $ 383,616 $ 190,008 $ 193,608 $ — Financial liabilities: Contingent consideration $ 11,300 — — $ 11,300 Total financial liabilities $ 11,300 — — $ 11,300 December 31, 2019 Reported as: Cash equivalents $ 136,997 Restricted cash 6,183 Marketable securities 240,436 Total cash equivalents, restricted cash, and marketable securities $ 383,616 Accrued liabilities $ 3,300 Other long-term liabilities $ 8,000 There were no transfers between Level 1, Level 2 and Level 3 during the periods presented. The total fair value of investments with unrealized losses at March 31, 2020 was nil . None of the available-for-sale securities held as of March 31, 2020 has been in a continuous unrealized loss position for more than one year. Interest income generated from our investments was $1.0 million and $0.6 million during the three months ended March 31, 2020 and 2019 , respectively. Our certificates of deposit and debt securities of U.S. government agency entities are classified as Level 2 as they are valued based upon quoted market prices for similar instruments in active markets, quoted prices for identical or similar instruments in markets that are not active and model-based valuation techniques for which all significant inputs are observable in the market or can be corroborated by observable market data for substantially the full term of the assets. Where applicable, these models project future cash flows and discount the future amounts to a present value using market-based observable inputs obtained from various third-party data providers, including but not limited to benchmark yields, interest rate curves, reported trades, broker/dealer quotes and reference data. Stock payable liabilities relate to certain indemnification hold-backs resulting from business combinations that are settled in shares of our common stock. We elected to account for these liabilities using the fair value option due to the inherent nature of the liabilities and the changes in value of the underlying shares that will ultimately be issued to settle the liabilities. The estimated fair value of these liabilities is classified as Level 3 and determined based upon the number of shares that are issuable to the sellers and the quoted closing price of our common stock as of the reporting date. The number of shares that will ultimately be issued is subject to adjustment for indemnified claims that existed as of the closing date for each acquisition. Changes in the number of shares issued and share price can significantly affect the estimated fair value of the liabilities. During the three months ended March 31, 2020 , the change in fair value related to stock payable liabilities recorded to other income, net was $3.4 million . As of March 31, 2020 , we had contingent obligations of $11.2 million of our common stock to the former owners of Jungla in conjunction with our acquisition of Jungla in July 2019. The amount of the contingent obligation is dependent upon achievement of certain post-close development milestones. We estimated the fair value of the contingent consideration as $10.7 million at the acquisition date in July 2019 using a discounted cash flow technique based on estimated achievement of the post-close milestones and discount rates which were Level 3 inputs not supported by market activity. These inputs can significantly affect the estimated fair value of the contingent consideration. The value of the liability is subsequently remeasured to fair value at each reporting date with changes recorded as general and administrative expense.

Commitments and contingencies

Commitments and contingencies	3 Months Ended
	Mar. 31, 2020
Commitments and Contingencies Disclosure [Abstract]
Commitments and contingencies	Commitments and contingencies Leases Operating leases In 2015, we entered into a lease agreement for our headquarters and main production facility in San Francisco, California which commenced in 2016. This lease expires in 2026 and we may renew the lease for an additional ten years . This optional period was not considered reasonably certain to be exercised and therefore we determined the lease term to be a ten -year period expiring in 2026. In connection with the execution of the lease, we provided a security deposit of approximately $4.6 million which is included in restricted cash in our consolidated balance sheets. We also have other operating leases for office and laboratory space in California, Massachusetts and New York. We expect to enter into new leases and modifying existing leases as we support continued growth of our operations. As of March 31, 2020 , the weighted-average remaining lease term for our operating leases was 6.3 years and the weighted-average discount rate used to determine our operating lease liability was 11.6% . Cash payments included in the measurement of our operating lease liabilities were $2.7 million for the three months ended March 31, 2020 . The components of lease costs, which were included in cost of revenue, research and development, selling and marketing and general and administrative expenses on our consolidated statements of operations were as follows (in thousands): Three Months Ended March 31, 2020 2019 Operating lease costs $ 2,615 $ 2,517 Sublease income — (43 ) Total operating lease costs 2,615 2,474 Finance lease costs 484 420 Total lease costs $ 3,099 $ 2,894 Future minimum payments under non-cancelable operating leases as of March 31, 2020 are as follows (in thousands): 2020 (remainder of year) $ 7,770 2021 10,671 2022 10,631 2023 10,424 2024 10,560 Thereafter 18,459 Future non-cancelable minimum operating lease payments 68,515 Less: imputed interest (20,623 ) Total operating lease liabilities 47,892 Less: current portion (5,125 ) Operating lease obligations, net of current portion $ 42,767 Finance leases We have entered into various finance lease agreements to obtain laboratory equipment. The terms of our finance leases are generally three years with a weighted-average remaining lease term of 2.0 years as of March 31, 2020 and are typically secured by the underlying equipment. The weighted-average discount rate used to determine our finance lease liability was 5.7% . The portion of the future payments designated as principal repayment was classified as a finance lease obligation on our consolidated balance sheets. Finance lease assets are recorded within other assets on our consolidated balance sheet and were $5.1 million and $5.6 million as of March 31, 2020 and December 31, 2019 , respectively. Cash payments included in the measurement of our finance lease liabilities were $0.7 million and $0.5 million for the three months ended March 31, 2020 and 2019 , respectively. Future payments under finance leases at March 31, 2020 are as follows (in thousands): 2020 (remainder of year) $ 1,306 2021 611 2022 611 Total finance lease obligations 2,528 Less: interest (139 ) Present value of net minimum finance lease payments 2,389 Less: current portion (1,370 ) Finance lease obligations, net of current portion $ 1,019 Debt financing In November 2018, we entered into a Note Purchase Agreement (the "2018 Note Purchase Agreement") pursuant to which we were eligible to borrow an aggregate principal amount up to $200.0 million over a seven year maturity term which included an initial borrowing of $75.0 million in November 2018. We received net proceeds of $10.3 million after terminating and repaying the balance of our obligations of approximately $64.7 million with our previous lender. In September 2019, we settled our obligations under the 2018 Note Purchase Agreement in full for $85.7 million , which included repayment of principal of $75.0 million , accrued interest of $2.4 million , and prepayment fees of $8.9 million which were recorded as debt extinguishment costs in other income (expense), net in our statement of operations during the three months ended September 30, 2019. Interest expense related to our debt financings, excluding the impact of our Convertible Senior Notes, was nil and $2.0 million for the three months ended March 31, 2020 and 2019 , respectively. Convertible Senior Notes In September 2019, we issued, at par value, $350.0 million aggregate principal amount of 2.00% Convertible Senior Notes due 2024 in a private offering. The Convertible Senior Notes are our senior unsecured obligations and will mature on September 1, 2024, unless earlier converted, redeemed or repurchased. The Convertible Senior Notes bear cash interest at a rate of 2.0% per year, payable semi-annually in arrears on March 1 and September 1 of each year, beginning on March 1, 2020. Upon conversion, the Convertible Senior Notes will be convertible into cash, shares of our common stock or a combination of cash and shares of our common stock, at our election. Our current intent is to settle the principal amount of the Convertible Senior Notes in cash upon conversion, with any remaining conversion value being delivered in shares of our common stock. The initial conversion rate for the Convertible Senior Notes is 33.6293 shares of our common stock per $1,000 principal amount of the Convertible Senior Notes (equivalent to an initial conversion price of approximately $29.74 per share of common stock). If we undergo a fundamental change (as defined in the indenture governing the Convertible Senior Notes), the holders of the Convertible Senior Notes may require us to repurchase all or any portion of their Convertible Senior Notes for cash at a repurchase price equal to 100% of the principal amount of the Convertible Senior Notes to be repurchased plus accrued and unpaid interest to, but excluding, the redemption date. The Convertible Senior Notes will be convertible at the option of the holders at any time prior to the close of business on the business day immediately preceding March 1, 2024, only under the following circumstances: (1) during any calendar quarter commencing after the calendar quarter ending on December 31, 2019 (and only during such calendar quarter), if the last reported sale price of our common stock for at least 20 trading days (whether or not consecutive) during a period of 30 consecutive trading days ending on, and including, the last trading day of the immediately preceding calendar quarter is greater than or equal to 130% of the conversion price for the Convertible Senior Notes on each applicable trading day; (2) during the five business day period after any five consecutive trading day period (the “measurement period”) in which the trading price per $1,000 principal amount of Convertible Senior Notes for each trading day of the measurement period was less than 98% of the product of the last reported sale price of our common stock and the conversion rate on each such trading day; (3) if we call any or all of the Convertible Senior Notes for redemption, at any time prior to the close of business on the scheduled trading day immediately preceding the redemption date; or (4) upon the occurrence of specified corporate events. On or after March 1, 2024 until the close of business on the business day immediately preceding the maturity date, holders may convert their Convertible Senior Notes at any time, regardless of the foregoing circumstances. As of March 31, 2020 , none of the above circumstances had occurred and therefore the Convertible Senior Notes could not have been converted. We may not redeem the Convertible Senior Notes prior to September 6, 2022. We may redeem for cash all or any portion of the Convertible Senior Notes, at our option, on or after September 6, 2022 and on or before the 30 th scheduled trading day immediately before the maturity date if the last reported sale price of the Common Stock has been at least 130% of the conversion price then in effect for at least 20 trading days (whether or not consecutive) during any 30 consecutive trading day period (including the last trading day of such period) ending on, and including, the trading day immediately preceding the date on which we provide notice of redemption at a redemption price equal to 100% of the principal amount of the notes to be redeemed, plus accrued and unpaid interest to, but excluding, the redemption date. The Convertible Senior Notes as of March 31, 2020 consisted of the following (in thousands): Outstanding principal $ 350,000 Unamortized debt discount and issuance costs (77,613 ) Net carrying amount, liability component $ 272,387 As of March 31, 2020 , the fair value of the Convertible Senior Notes was $310.8 million . The estimated fair value of the Convertible Senior Notes, which are classified as Level 2 financial instruments, was determined based on the estimated or actual bid prices of the Convertible Senior Notes in an over-the-counter market. We recognized $5.4 million of interest expense related to the Convertible Senior Notes during the three months ended March 31, 2020 . Other commitments In the normal course of business, we enter into various purchase commitments primarily related to service agreements and laboratory supplies. At March 31, 2020 , our total future payments under noncancelable unconditional purchase commitments having a remaining term of over one year were $9.2 million . Guarantees and indemnifications As permitted under Delaware law and in accordance with our bylaws, we indemnify our directors and officers for certain events or occurrences while the officer or director is or was serving in such capacity. The maximum amount of potential future indemnification is unlimited; however, we maintain director and officer liability insurance. This insurance allows the transfer of the risk associated with our exposure and may enable us to recover a portion of any future amounts paid. We believe the fair value of these indemnification agreements is minimal. Accordingly, we did not record any liabilities associated with these indemnification agreements at March 31, 2020 or December 31, 2019 . Contingencies We were not a party to any material legal proceedings at March 31, 2020 , or at the date of this report. We are and may from time to time become involved in various legal proceedings and claims arising in the ordinary course of business. While we believe any such claims are unsubstantiated, and we believe we are in compliance with applicable laws and regulations applicable to our business, the resolution of any such claims could be material.

Stockholders' equity

Stockholders' equity	3 Months Ended
	Mar. 31, 2020
Equity [Abstract]
Stockholders' equity	Stockholders’ equity Shares outstanding Shares of convertible preferred and common stock were as follows (in thousands): Three Months Ended March 31, 2020 2019 Convertible preferred stock: Shares outstanding, beginning of period 125 3,459 Conversion into common stock — (3,334 ) Shares outstanding, end of period 125 125 Common stock: Shares outstanding, beginning of period 98,796 75,481 Common stock issued in connection with public offering — 10,350 Common stock issued on exercise of stock options, net 178 260 Common stock issued pursuant to vesting of RSUs 426 121 Common stock issued pursuant to exercises of warrants 142 15 Common stock issued pursuant to business combinations 2,378 40 Common stock issued upon conversion of preferred stock — 3,334 Shares outstanding, end of period 101,920 89,601

Stock incentive plans

Stock incentive plans	3 Months Ended
	Mar. 31, 2020
Share-based Payment Arrangement [Abstract]
Stock incentive plans	Stock incentive plans Stock incentive plans In 2010, we adopted the 2010 Incentive Plan (the “2010 Plan”). The 2010 Plan provides for the granting of stock-based awards to employees, directors and consultants under terms and provisions established by our Board of Directors. Under the terms of the 2010 Plan, options may be granted at an exercise price not less than the fair market value of our common stock. For employees holding more than 10% of the voting rights of all classes of stock, the exercise prices for incentive and nonstatutory stock options must be at least 110% of fair market of our common stock on the grant date, as determined by our Board of Directors. The terms of options granted under the 2010 Plan may not exceed ten years . In January 2015, we adopted the 2015 Stock Incentive Plan (the “2015 Plan”), which became effective upon the closing of our initial public offering (“IPO”). Shares outstanding under the 2010 Plan were transferred to the 2015 Plan upon effectiveness of the 2015 Plan. The 2015 Plan provides for automatic annual increases in shares available for grant, beginning on January 1, 2016 through January 1, 2025. In addition, shares subject to awards under the 2010 Plan that are forfeited or terminated will be added to the 2015 Plan. The 2015 Plan provides for the grant of incentive stock options, nonstatutory stock options, restricted stock awards, stock units, stock appreciation rights and other forms of equity compensation, all of which may be granted to employees, including officers, non-employee directors and consultants. Additionally, the 2015 Plan provides for the grant of cash-based awards. In June 2019, we amended and restated the 2015 Plan to create a pool of shares to be awarded solely as a material inducement to employees. Options granted generally vest over a period of four years . Typically, the vesting schedule for options granted to newly hired employees provides that 1/4 of the award vests upon the first anniversary of the employee’s date of hire, with the remainder of the award vesting monthly thereafter at a rate of 1/48 of the total shares subject to the option. All other options typically vest in equal monthly installments over the four-year vesting schedule. RSUs generally vest over a period of three years . Typically, the vesting schedule for RSUs provides that 1/3 of the award vests upon each anniversary of the grant date, with certain awards that include a portion that vests immediately upon grant. In June 2019, we granted Time-based RSUs in connection with the acquisition of Singular Bio which vest in three equal installments over a period of 18 months and PRSUs that vest based on the achievement of performance conditions; see further details in Note 4, "Business combinations." Under our management incentive compensation plan, in July 2019 we granted PRSUs to our executive officers as well as other specified senior level employees based on the level of achievement of a specified 2019 revenue goal. One-third of the 0.8 million shares that were ultimately awarded under this plan vested during the three months ended March 31, 2020 and the remaining awards will continue to vest over a period of two years . Activity under the 2010 Plan and the 2015 Plan is set forth below (in thousands, except per share amounts and years): Shares Available For Grant Stock Options Outstanding Weighted-Average Exercise Price Per Share Weighted-Average Remaining Contractual Life (Years) Aggregate Intrinsic Value Balances at December 31, 2019 5,444 3,542 $ 9.49 6.1 $ 24,966 Additional shares reserved 4,552 — Options exercised — (178 ) 6.44 RSUs and PRSUs granted (1) (1,223 ) — RSUs and PRSUs cancelled 232 — Balances at March 31, 2020 9,005 3,364 $ 9.66 5.9 $ 15,430 Options exercisable at March 31, 2020 2,954 $ 8.98 5.6 $ 14,187 Options vested and expected to vest at March 31, 2020 3,311 $ 9.56 5.9 $ 15,290 (1) Includes the changes in the Time-based RSUs and PRSUs granted as a part of the Singular Bio acquisition in June 2019 which are based on a fixed dollar value. The number of shares issued will be variable until the awards vest. See further details in Note 4, "Business combinations." The aggregate intrinsic value is calculated as the difference between the exercise price of the underlying stock options and the fair value of our common stock for stock options that were in-the-money. The total grant-date fair value of options to purchase common stock vested was $0.7 million and $1.1 million in the three months ended March 31, 2020 and 2019 , respectively. The intrinsic value of options to purchase common stock exercised was $2.3 million and $3.3 million in the three months ended March 31, 2020 and 2019 , respectively. The following table summarizes RSU activity, which includes the changes in Time-based RSUs and PRSUs granted in connection with our acquisition of Singular Bio (in thousands, except per share data): Number of Shares Weighted- Average Grant Date Fair Value Per Share Balance at December 31, 2019 8,885 $ 15.17 RSUs granted 218 $ 17.89 Time-based RSUs and PRSUs granted - Singular Bio (1) 1,005 $ 13.67 RSUs vested (426 ) $ 18.00 RSUs cancelled (232 ) $ 20.27 Balance at March 31, 2020 9,450 $ 14.82 (1) Includes the changes in the Time-based RSUs and PRSUs granted as a part of the Singular Bio acquisition in June 2019 which are based on a fixed dollar value. The number of shares issued will be variable until the awards vest. The weighted-average grant date fair value per share reflects the fair value pricing of the full award. See further details in Note 4, "Business combinations." 2015 Employee Stock Purchase Plan In January 2015, we adopted the 2015 Employee Stock Purchase Plan (the “ESPP”), which became effective upon the closing of the IPO. Employees participating in the ESPP may purchase common stock at 85% of the lesser of the fair market value of common stock on the purchase date or last trading day preceding the offering date. At March 31, 2020 , cash received from payroll deductions pursuant to the ESPP was $3.4 million . At March 31, 2020 , a total of 1.6 million shares of common stock were reserved for issuance under the ESPP. Stock-based compensation The following table summarizes stock-based compensation expense included in the consolidated statements of operations (in thousands): Three Months Ended March 31, 2020 2019 Cost of revenue $ 861 $ 651 Research and development 22,204 1,805 Selling and marketing 1,823 1,243 General and administrative 4,390 1,524 Total stock-based compensation expense $ 29,278 $ 5,223

Net loss per share

Net loss per share	3 Months Ended
	Mar. 31, 2020
Earnings Per Share [Abstract]
Net loss per share	Net loss per share The following table presents the calculation of basic and diluted net loss per share (in thousands, except per share amounts): Three Months Ended March 31, 2020 2019 Net loss $ (98,527 ) $ (37,677 ) Shares used in computing net loss per share, basic and diluted 99,632 79,369 Net loss per share, basic and diluted $ (0.99 ) $ (0.47 ) The following common stock equivalents have been excluded from diluted net loss per share because their inclusion would be anti-dilutive (in thousands): Three Months Ended March 31, 2020 2019 Shares of common stock subject to outstanding options 3,478 3,759 Shares of common stock subject to outstanding warrants 489 609 Shares of common stock subject to outstanding RSUs 5,703 4,130 Shares of common stock subject to outstanding PRSUs 3,988 — Shares of common stock pursuant to ESPP 368 213 Shares of common stock underlying Series A convertible preferred stock 125 2,465 Shares of common stock subject to convertible senior notes exercise 11,770 — Total shares of common stock equivalents 25,921 11,176

Geographic information

Geographic information	3 Months Ended
	Mar. 31, 2020
Segments, Geographical Areas [Abstract]
Geographic information	Geographic information Revenue by country is determined based on the billing address of the customer. The following presents revenue by country (in thousands): Three Months Ended March 31, 2020 2019 United States $ 59,806 $ 37,645 Canada 1,219 965 Rest of world 3,223 1,943 Total revenue $ 64,248 $ 40,553

Subsequent events

Subsequent events	3 Months Ended
	Mar. 31, 2020
Subsequent Events [Abstract]
Subsequent events	Subsequent events YouScript and Genelex In March 2020, we entered into definitive agreements for 100% of the capital stock of YouScript, a privately held clinical decision support analytics platform, and Genelex, a privately held pharmacogenetic testing company. These transactions were subject to certain closing conditions which were satisfied in April 2020 at which point the transactions were consummated. At the closing of the transaction with YouScript, we issued an aggregate of 1.8 million shares of our common stock and approximately $23.6 million in cash to former securityholders of YouScript. Up to approximately $1.4 million in cash and 0.5 million additional shares of our common stock are subject to a hold-back to satisfy indemnification obligations that may arise following the closing of our acquisition of YouScript. At the closing of the transaction with Genelex, we issued an aggregate of 0.8 million shares and to former securityholders of Genelex. Up to 0.1 million of additional shares are subject to a hold back to satisfy indemnification obligations that may arise following the closing of our acquisition of Genelex. We would also become obligated pursuant to the terms of the Genelex acquisition agreement to issue additional shares of common stock to the former securityholders of Genelex if, within a specified period following the closing, Genelex achieves a certain product milestone, in which case we would thereafter issue to the former securityholders of Genelex shares of our common stock with a value equal to a portion of the gross revenues actually received by us for that product and similar products during an earn-out period of up to four years . Given the timing of the closing of these transactions, we are currently in the process of valuing the assets acquired and liabilities assumed. As a result, we are not yet able to provide the amounts to be recognized as of the acquisition dates for the major classes of assets acquired and liabilities assumed and other related disclosures. We expect to disclose this and other related information in our Form 10-Q for the quarter ending June 30, 2020. Public offering In April 2020, we issued, in an underwritten public offering, an aggregate of 20.4 million shares of our common stock at a price of $9.00 per share, for gross proceeds of $184.0 million and net proceeds of approximately $173.0 million after deducting underwriting discounts and commissions and offering expenses.

Summary of significant accoun_2

Summary of significant accounting policies (Policies)	3 Months Ended
	Mar. 31, 2020
Accounting Policies [Abstract]
Basis of presentation	Basis of presentation The accompanying unaudited condensed consolidated financial statements have been prepared in accordance with U.S. generally accepted accounting principles (“U.S. GAAP”) for interim financial information and in accordance with the instructions to Form 10-Q and Rule 10-01 of Regulation S-X. Accordingly, they do not include all of the information and footnotes required by generally accepted accounting principles for complete financial statements. The unaudited interim condensed consolidated financial statements have been prepared on the same basis as the annual financial statements. In the opinion of management, the accompanying unaudited condensed consolidated financial statements reflect all adjustments (consisting only of normal recurring adjustments) considered necessary for a fair presentation. The information included in this Quarterly Report on Form 10-Q should be read in conjunction with the audited financial statements and notes thereto included in our Annual Report on Form 10-K for the year ended December 31, 2019 . The results for the three months ended March 31, 2020 are not necessarily indicative of the results expected for the full fiscal year or any other periods.
Principles of consolidation	Principles of consolidation Our unaudited condensed consolidated financial statements include our accounts and the accounts of our wholly-owned subsidiaries. All intercompany balances and transactions have been eliminated in consolidation.
Use of estimates	Use of estimates The preparation of financial statements in conformity with U.S. GAAP requires management to make judgments, estimates and assumptions that affect the reported amounts of assets and liabilities and disclosure of contingent liabilities as of the date of the financial statements and the reported amounts of revenue and expenses during the reporting period. We base these estimates on current facts, historical and anticipated results, trends and various other assumptions that we believe are reasonable under the circumstances, including assumptions as to future events. Actual results could differ materially from those judgments, estimates and assumptions. We evaluate our estimates on an ongoing basis.
Concentrations of credit risk and other risks and uncertainties	Concentrations of credit risk and other risks and uncertainties Financial instruments that potentially subject us to a concentration of credit risk consist of cash, cash equivalents, marketable securities and accounts receivable. Our cash and cash equivalents are held by financial institutions in the United States. Such deposits may exceed federally insured limits.
Inventory	Inventory
Fair value of financial instruments	Fair value of financial instruments Our financial instruments consist principally of cash and cash equivalents, marketable securities, accounts payable, accrued liabilities, finance leases and liabilities associated with business combinations. The carrying amounts of certain of these financial instruments, including cash and cash equivalents, accounts receivable, accounts payable and accrued and other current liabilities approximate their current fair value due to the relatively short-term nature of these accounts. Based on borrowing rates available to us, the carrying value of our finance leases approximate their fair values. Liabilities associated with business combinations are recorded at their estimated fair value.
Prior period reclassifications	Prior period reclassifications We have reclassified certain amounts in prior periods to conform with current presentation.
Recent accounting pronouncements	Recent accounting pronouncements We evaluate all Accounting Standards Updates (“ASUs”) issued by the Financial Accounting Standards Board ("FASB") for consideration of their applicability. ASUs not included in the disclosures in this report were assessed and determined to be either not applicable or are not expected to have a material impact on our consolidated financial statements. Recently adopted accounting pronouncements In June 2016, FASB issued ASU 2016-13, Financial Instruments-Credit Losses (Topic 326), which requires measurement and recognition of expected credit losses for financial assets. This guidance became effective for us beginning in the first quarter of 2020 and was adopted using a modified retrospective approach, with certain exceptions. The adoption of Topic 326 did not have a material impact on our consolidated financial statements as credit losses are not expected to be significant. As part of our adoption of Topic 326, we assess our accounts receivables for expected credit losses at each reporting period by disaggregating by payer type and further by portfolios of customers with similar characteristics, such as customer type and geographic location. We then review each portfolio for expected credit losses based on historical payment trends as well as forward looking data and current economic trends. If a credit loss is determined, we record a reduction to our accounts receivable balance with a corresponding general and administrative expense.

Summary of significant accoun_3

Summary of significant accounting policies (Tables)	3 Months Ended
	Mar. 31, 2020
Accounting Policies [Abstract]
Summary of significant customers as percentage of total revenue and total accounts receivable	Our revenue from significant customers as a percentage of our total revenue was as follows: Three Months Ended March 31, 2020 2019 Medicare 21 % 22 %
Summary of restrictions on cash and cash equivalents	The following table provides a reconciliation of cash, cash equivalents and restricted cash reported within the consolidated balance sheets that sum to the total of the same amounts shown in the statements of cash flows (in thousands): March 31, December 31, Cash and cash equivalents $ 90,220 $ 151,389 Restricted cash 6,343 6,183 Total cash, cash equivalents and restricted cash $ 96,563 $ 157,572
Schedule of cash and cash equivalents	The following table provides a reconciliation of cash, cash equivalents and restricted cash reported within the consolidated balance sheets that sum to the total of the same amounts shown in the statements of cash flows (in thousands): March 31, December 31, Cash and cash equivalents $ 90,220 $ 151,389 Restricted cash 6,343 6,183 Total cash, cash equivalents and restricted cash $ 96,563 $ 157,572

Revenue, accounts receivable _2

Revenue, accounts receivable and deferred revenue (Tables)	3 Months Ended
	Mar. 31, 2020
Revenue from Contract with Customer [Abstract]
Schedule of disaggregated revenue by payer category	The following table includes our revenues as disaggregated by payer category (in thousands): Three Months Ended March 31, 2020 2019 Test revenue: Institutions $ 13,497 $ 8,154 Patient - direct 5,791 3,741 Patient - insurance 43,790 27,724 Total test revenue 63,078 39,619 Other revenue 1,170 934 Total revenue $ 64,248 $ 40,553
Schedule of change in estimate	As a result of new information, we updated our estimate of the amounts to be recognized for previously delivered tests which resulted in the following increases to revenue and decreases to our loss from operations and basic and diluted net loss per share (in millions, except per share amounts): Three Months Ended March 31, 2020 2019 Revenue $ 1.4 $ 0.4 Loss from operations $ (1.4 ) $ (0.4 ) Net loss per share, basic and diluted $ (0.01 ) $ (0.01 )

Business combinations (Tables)

Business combinations (Tables)	3 Months Ended
	Mar. 31, 2020
Business Combinations [Abstract]
Summary of purchase price and post-combination expense	The following table summarizes the purchase price recorded as a part of the acquisition of Diploid (in thousands): Purchase Price Cash transferred $ 32,323 Hold-back consideration - common stock 7,538 Common stock transferred 42,453 Total $ 82,314
Summary of fair values of assets acquired and liabilities assumed	The following table summarizes the fair values of assets acquired and liabilities assumed through our acquisition of Diploid at the date of acquisition (in thousands): Cash $ 124 Accounts receivable 26 Developed technology 41,789 Total identifiable assets acquired 41,939 Accounts payable (30 ) Deferred tax liability (10,250 ) Net identifiable assets acquired 31,659 Goodwill 50,655 Total purchase price $ 82,314

Goodwill and intangible assets

Goodwill and intangible assets (Tables)	3 Months Ended
	Mar. 31, 2020
Goodwill and Intangible Assets Disclosure [Abstract]
Summary of goodwill	The changes in the carrying amounts of goodwill were as follows (in thousands): Balance as of December 31, 2019 $ 126,777 Goodwill acquired - Diploid 50,655 Balance as of March 31, 2020 $ 177,432
Schedule of intangible assets	The following table presents details of our intangible assets (in thousands): March 31, 2020 December 31, 2019 Cost Accumulated Net Weighted-Average Cost Accumulated Net Weighted-Average Customer relationships $ 23,763 $ (5,841 ) $ 17,922 10.0 $ 23,763 $ (5,141 ) $ 18,622 10.0 Developed technology 126,185 (11,291 ) 114,894 8.7 84,396 (8,476 ) 75,920 8.6 Non-compete agreement 286 (186 ) 100 5.0 286 (172 ) 114 5.0 Trade name 576 (519 ) 57 2.7 576 (480 ) 96 2.7 Patent licensing agreement 496 (79 ) 417 15.0 496 (70 ) 426 15.0 Favorable leases 247 (247 ) — 2.2 247 (238 ) 9 2.2 In-process research and development 29,988 — 29,988 n/a 29,988 — 29,988 n/a $ 181,541 $ (18,163 ) $ 163,378 8.9 $ 139,752 $ (14,577 ) $ 125,175 8.9
Schedule of intangible assets	The following table presents details of our intangible assets (in thousands): March 31, 2020 December 31, 2019 Cost Accumulated Net Weighted-Average Cost Accumulated Net Weighted-Average Customer relationships $ 23,763 $ (5,841 ) $ 17,922 10.0 $ 23,763 $ (5,141 ) $ 18,622 10.0 Developed technology 126,185 (11,291 ) 114,894 8.7 84,396 (8,476 ) 75,920 8.6 Non-compete agreement 286 (186 ) 100 5.0 286 (172 ) 114 5.0 Trade name 576 (519 ) 57 2.7 576 (480 ) 96 2.7 Patent licensing agreement 496 (79 ) 417 15.0 496 (70 ) 426 15.0 Favorable leases 247 (247 ) — 2.2 247 (238 ) 9 2.2 In-process research and development 29,988 — 29,988 n/a 29,988 — 29,988 n/a $ 181,541 $ (18,163 ) $ 163,378 8.9 $ 139,752 $ (14,577 ) $ 125,175 8.9
Summary of estimated future amortization expense of intangible assets with finite lives	The following table summarizes our estimated future amortization expense of intangible assets with finite lives as of March 31, 2020 (in thousands): 2020 (remainder of year) $ 13,568 2021 18,426 2022 16,721 2023 15,708 2024 15,430 Thereafter 53,537 Total estimated future amortization expense $ 133,390

Balance sheet components (Table

Balance sheet components (Tables)	3 Months Ended
	Mar. 31, 2020
Balance Sheet Related Disclosures [Abstract]
Schedule of property and equipment	Property and equipment consisted of the following (in thousands): March 31, 2020 December 31, 2019 Leasehold improvements $ 21,422 $ 18,352 Laboratory equipment 26,983 24,873 Computer equipment 6,476 5,995 Software 2,611 2,611 Furniture and fixtures 1,277 1,198 Automobiles 58 58 Construction-in-progress 10,239 10,795 Total property and equipment, gross 69,066 63,882 Accumulated depreciation and amortization (27,981 ) (26,135 ) Total property and equipment, net $ 41,085 $ 37,747
Schedule of accrued liabilities	Accrued liabilities consisted of the following (in thousands): March 31, 2020 December 31, 2019 Accrued compensation and related expenses $ 18,927 $ 16,440 Compensation and other liabilities associated with business combinations 55,789 30,560 Deferred revenue 1,460 1,429 Other 12,617 16,385 Total accrued liabilities $ 88,793 $ 64,814

Fair value measurements (Tables

Fair value measurements (Tables)	3 Months Ended
	Mar. 31, 2020
Fair Value Disclosures [Abstract]
Financial instruments at fair value on a recurring basis	The following tables set forth the fair value of our consolidated financial instruments that were measured at fair value on a recurring basis (in thousands): March 31, 2020 Amortized Cost Unrealized Estimated Fair Value Gains Losses Level 1 Level 2 Level 3 Financial assets: Money market funds $ 32,653 $ — $ — $ 32,653 $ 32,653 $ — $ — Certificates of deposit 300 — — 300 — 300 — U.S. treasury notes 137,937 1,157 — 139,094 139,094 — — U.S. government agency securities 64,857 137 — 64,994 — 64,994 — Total financial assets $ 235,747 $ 1,294 $ — $ 237,041 $ 171,747 $ 65,294 $ — Financial liabilities: Stock payable liability $ 14,362 $ — $ — $ 14,362 Contingent consideration 11,200 — — 11,200 Total financial liabilities $ 25,562 $ — $ — $ 25,562 March 31, 2020 Reported as: Cash equivalents $ 26,310 Restricted cash 6,343 Marketable securities 204,388 Total cash equivalents, restricted cash, and marketable securities $ 237,041 Accrued liabilities $ 8,500 Other long-term liabilities $ 17,062 December 31, 2019 Amortized Cost Unrealized Estimated Fair Value Gains Losses Level 1 Level 2 Level 3 Financial assets: Money market funds $ 39,396 $ — $ — $ 39,396 $ 39,396 $ — $ — Certificates of deposit 300 — — 300 — 300 — U.S. treasury notes 150,627 — (15 ) 150,612 150,612 — — U.S. government agency securities 193,302 6 — 193,308 — 193,308 — Total financial assets $ 383,625 $ 6 $ (15 ) $ 383,616 $ 190,008 $ 193,608 $ — Financial liabilities: Contingent consideration $ 11,300 — — $ 11,300 Total financial liabilities $ 11,300 — — $ 11,300 December 31, 2019 Reported as: Cash equivalents $ 136,997 Restricted cash 6,183 Marketable securities 240,436 Total cash equivalents, restricted cash, and marketable securities $ 383,616 Accrued liabilities $ 3,300 Other long-term liabilities $ 8,000

Commitments and contingencies (

Commitments and contingencies (Tables)	3 Months Ended
	Mar. 31, 2020
Commitments and Contingencies Disclosure [Abstract]
Components of lease cost	The components of lease costs, which were included in cost of revenue, research and development, selling and marketing and general and administrative expenses on our consolidated statements of operations were as follows (in thousands): Three Months Ended March 31, 2020 2019 Operating lease costs $ 2,615 $ 2,517 Sublease income — (43 ) Total operating lease costs 2,615 2,474 Finance lease costs 484 420 Total lease costs $ 3,099 $ 2,894
Schedule of future minimum payments under operating leases	Future minimum payments under non-cancelable operating leases as of March 31, 2020 are as follows (in thousands): 2020 (remainder of year) $ 7,770 2021 10,671 2022 10,631 2023 10,424 2024 10,560 Thereafter 18,459 Future non-cancelable minimum operating lease payments 68,515 Less: imputed interest (20,623 ) Total operating lease liabilities 47,892 Less: current portion (5,125 ) Operating lease obligations, net of current portion $ 42,767
Schedule of future minimum lease payments under finance leases	Future payments under finance leases at March 31, 2020 are as follows (in thousands): 2020 (remainder of year) $ 1,306 2021 611 2022 611 Total finance lease obligations 2,528 Less: interest (139 ) Present value of net minimum finance lease payments 2,389 Less: current portion (1,370 ) Finance lease obligations, net of current portion $ 1,019
Components of debt	The Convertible Senior Notes as of March 31, 2020 consisted of the following (in thousands): Outstanding principal $ 350,000 Unamortized debt discount and issuance costs (77,613 ) Net carrying amount, liability component $ 272,387

Stockholders' equity (Tables)

Stockholders' equity (Tables)	3 Months Ended
	Mar. 31, 2020
Equity [Abstract]
Schedule of convertible preferred and common stock	Shares of convertible preferred and common stock were as follows (in thousands): Three Months Ended March 31, 2020 2019 Convertible preferred stock: Shares outstanding, beginning of period 125 3,459 Conversion into common stock — (3,334 ) Shares outstanding, end of period 125 125 Common stock: Shares outstanding, beginning of period 98,796 75,481 Common stock issued in connection with public offering — 10,350 Common stock issued on exercise of stock options, net 178 260 Common stock issued pursuant to vesting of RSUs 426 121 Common stock issued pursuant to exercises of warrants 142 15 Common stock issued pursuant to business combinations 2,378 40 Common stock issued upon conversion of preferred stock — 3,334 Shares outstanding, end of period 101,920 89,601

Stock incentive plans (Tables)

Stock incentive plans (Tables)	3 Months Ended
	Mar. 31, 2020
Share-based Payment Arrangement [Abstract]
Schedule of activity under the plans	Activity under the 2010 Plan and the 2015 Plan is set forth below (in thousands, except per share amounts and years): Shares Available For Grant Stock Options Outstanding Weighted-Average Exercise Price Per Share Weighted-Average Remaining Contractual Life (Years) Aggregate Intrinsic Value Balances at December 31, 2019 5,444 3,542 $ 9.49 6.1 $ 24,966 Additional shares reserved 4,552 — Options exercised — (178 ) 6.44 RSUs and PRSUs granted (1) (1,223 ) — RSUs and PRSUs cancelled 232 — Balances at March 31, 2020 9,005 3,364 $ 9.66 5.9 $ 15,430 Options exercisable at March 31, 2020 2,954 $ 8.98 5.6 $ 14,187 Options vested and expected to vest at March 31, 2020 3,311 $ 9.56 5.9 $ 15,290 (1) Includes the changes in the Time-based RSUs and PRSUs granted as a part of the Singular Bio acquisition in June 2019 which are based on a fixed dollar value. The number of shares issued will be variable until the awards vest. See further details in Note 4, "Business combinations."
Summary of RSU activity	The following table summarizes RSU activity, which includes the changes in Time-based RSUs and PRSUs granted in connection with our acquisition of Singular Bio (in thousands, except per share data): Number of Shares Weighted- Average Grant Date Fair Value Per Share Balance at December 31, 2019 8,885 $ 15.17 RSUs granted 218 $ 17.89 Time-based RSUs and PRSUs granted - Singular Bio (1) 1,005 $ 13.67 RSUs vested (426 ) $ 18.00 RSUs cancelled (232 ) $ 20.27 Balance at March 31, 2020 9,450 $ 14.82 (1) Includes the changes in the Time-based RSUs and PRSUs granted as a part of the Singular Bio acquisition in June 2019 which are based on a fixed dollar value. The number of shares issued will be variable until the awards vest. The weighted-average grant date fair value per share reflects the fair value pricing of the full award. See further details in Note 4, "Business combinations."
Summary of stock based compensation expense	The following table summarizes stock-based compensation expense included in the consolidated statements of operations (in thousands): Three Months Ended March 31, 2020 2019 Cost of revenue $ 861 $ 651 Research and development 22,204 1,805 Selling and marketing 1,823 1,243 General and administrative 4,390 1,524 Total stock-based compensation expense $ 29,278 $ 5,223

Net loss per share (Tables)

Net loss per share (Tables)	3 Months Ended
	Mar. 31, 2020
Earnings Per Share [Abstract]
Schedule of earnings per share, basic and diluted	The following table presents the calculation of basic and diluted net loss per share (in thousands, except per share amounts): Three Months Ended March 31, 2020 2019 Net loss $ (98,527 ) $ (37,677 ) Shares used in computing net loss per share, basic and diluted 99,632 79,369 Net loss per share, basic and diluted $ (0.99 ) $ (0.47 )
Schedule of antidilutive securities excluded from computation of earnings per share	The following common stock equivalents have been excluded from diluted net loss per share because their inclusion would be anti-dilutive (in thousands): Three Months Ended March 31, 2020 2019 Shares of common stock subject to outstanding options 3,478 3,759 Shares of common stock subject to outstanding warrants 489 609 Shares of common stock subject to outstanding RSUs 5,703 4,130 Shares of common stock subject to outstanding PRSUs 3,988 — Shares of common stock pursuant to ESPP 368 213 Shares of common stock underlying Series A convertible preferred stock 125 2,465 Shares of common stock subject to convertible senior notes exercise 11,770 — Total shares of common stock equivalents 25,921 11,176

Geographic information (Tables)

Geographic information (Tables)	3 Months Ended
	Mar. 31, 2020
Segments, Geographical Areas [Abstract]
Schedule of revenue by country	The following presents revenue by country (in thousands): Three Months Ended March 31, 2020 2019 United States $ 59,806 $ 37,645 Canada 1,219 965 Rest of world 3,223 1,943 Total revenue $ 64,248 $ 40,553

Organization and description _2

Organization and description of business - Additional Information (Details) gene in Thousands	3 Months Ended	12 Months Ended
	Mar. 31, 2020Segmentgene	Dec. 31, 2019business	Dec. 31, 2017business
Organization, Consolidation and Presentation of Financial Statements [Abstract]
Number of genes | gene	20
Number of businesses acquired | business		3	4
Number of operating segments | Segment	1

Summary of significant accoun_4

Summary of significant accounting policies - Summary of significant customers as percentage of total revenue and total accounts receivable (Details)	3 Months Ended
	Mar. 31, 2020	Mar. 31, 2019
Customer Concentration Risk | Revenue | Medicare
Summary Of Significant Accounting Policies [Line Items]
Concentration risk	21.00%	22.00%

Summary of significant accoun_5

Summary of significant accounting policies - Reconciliation of cash, cash equivalents and restricted cash (Details) - USD ($) $ in Thousands	Mar. 31, 2020	Dec. 31, 2019	Mar. 31, 2019	Dec. 31, 2018
Accounting Policies [Abstract]
Cash and cash equivalents	$ 90,220	$ 151,389
Restricted cash	6,343	6,183
Total cash, cash equivalents and restricted cash	$ 96,563	$ 157,572	$ 258,373	$ 118,164

Summary of significant accoun_6

Summary of significant accounting policies - Additional information (Details) - USD ($) $ in Thousands	3 Months Ended
	Mar. 31, 2020	Mar. 31, 2019	Dec. 31, 2019	Dec. 31, 2018
Business Acquisition [Line Items]
Inventory	$ 13,300		$ 6,600
Stockholders' equity	326,133	$ 316,412	379,640
Other income, net	4,708	638
Immaterial error related to classification of Indemnification from acquisition | Restatement adjustment
Business Acquisition [Line Items]
Long-term liabilities	10,100
Other income, net	300
Additional paid-in capital:
Business Acquisition [Line Items]
Stockholders' equity	$ 1,182,033	$ 870,784	1,138,316	$ 678,548
Additional paid-in capital: | Immaterial error related to classification of Indemnification from acquisition | Restatement adjustment
Business Acquisition [Line Items]
Stockholders' equity			$ (10,387)

Revenue, accounts receivable _3

Revenue, accounts receivable and deferred revenue - Schedule of disaggregated revenue by payer category (Details) - USD ($) $ in Thousands	3 Months Ended
	Mar. 31, 2020	Mar. 31, 2019
Disaggregation of Revenue [Line Items]
Total revenue	$ 64,248	$ 40,553
Test revenue
Disaggregation of Revenue [Line Items]
Total revenue	63,078	39,619
Test revenue | Institutions
Disaggregation of Revenue [Line Items]
Total revenue	13,497	8,154
Test revenue | Patient - direct
Disaggregation of Revenue [Line Items]
Total revenue	5,791	3,741
Test revenue | Patient - insurance
Disaggregation of Revenue [Line Items]
Total revenue	43,790	27,724
Other revenue
Disaggregation of Revenue [Line Items]
Total revenue	$ 1,170	$ 934

Revenue, accounts receivable _4

Revenue, accounts receivable and deferred revenue - Schedule of change in estimate (Details) - USD ($) $ / shares in Units, $ in Thousands	3 Months Ended
	Mar. 31, 2020	Mar. 31, 2019
Revenue, Initial Application Period Cumulative Effect Transition [Line Items]
Total revenue	$ 64,248	$ 40,553
Change in loss from operations	$ 97,784	$ 36,207
Net loss per share, basic and diluted	$ 0.99	$ 0.47
Change in estimate of revenue recognition
Revenue, Initial Application Period Cumulative Effect Transition [Line Items]
Total revenue	$ 1,400	$ 400
Change in loss from operations	$ (1,400)	$ (400)
Net loss per share, basic and diluted	$ (0.01)	$ (0.01)

Revenue, accounts receivable _5

Revenue, accounts receivable and deferred revenue - Additional information (Details) - USD ($) $ in Millions	1 Months Ended		3 Months Ended
	May 31, 2020	Apr. 30, 2020	Jun. 30, 2020	Mar. 31, 2020
Restructuring Cost and Reserve [Line Items]
Revenue re-requisition rights period				90 days
One-time termination costs | Forecast
Restructuring Cost and Reserve [Line Items]
Restructuring charges			$ 3.8
Reduction in officer salary	20.00%
Subsequent event | One-time termination costs
Restructuring Cost and Reserve [Line Items]
Positions eliminated, percent of total workforce		8.00%
CARES Act | Subsequent event
Restructuring Cost and Reserve [Line Items]
Income received under the CARES Act		$ 3.8

Business combinations - Singula

Business combinations - Singular Bio (Details) - USD ($) $ in Thousands	1 Months Ended	3 Months Ended
	Jun. 30, 2019	Mar. 31, 2020	Mar. 31, 2019
Business Acquisition [Line Items]
Total stock-based compensation expense		$ 29,278	$ 5,223
Singular Bio
Business Acquisition [Line Items]
Percentage of diluted interest acquired	100.00%
Business combination, total purchase consideration	$ 57,300
Common stock transferred	$ 53,900
Business acquisition common stock issued (in shares)	2,500,000
Stock incentive plans
Business Acquisition [Line Items]
Vesting period		4 years
Stock incentive plans | Singular Bio
Business Acquisition [Line Items]
RSUs granted (in shares)		6,200,000
Restricted Stock Units (RSUs)
Business Acquisition [Line Items]
RSUs granted (in shares)		218,000
Vested stock units awarded (in shares)		426,000
Restricted Stock Units (RSUs) | Stock incentive plans
Business Acquisition [Line Items]
Vesting period		3 years
Restricted Stock Units (RSUs) | Stock incentive plans | Singular Bio
Business Acquisition [Line Items]
Business acquisition, value of units granted	$ 90,000
RSU - Service based | Stock incentive plans | Singular Bio
Business Acquisition [Line Items]
Business acquisition, value of units granted	45,000
Total stock-based compensation expense		$ 7,600
Fair value		$ 43,100
Vested stock units awarded (in shares)		800,000
Performance Restricted Stock Units (PRSUs) | Stock incentive plans | Singular Bio
Business Acquisition [Line Items]
Business acquisition, value of units granted	$ 45,000
Vesting period	12 months	18 months
Total stock-based compensation expense		$ 11,200
Fair value		$ 44,400
Vested stock units awarded (in shares)		0
First anniversary | Restricted Stock Units (RSUs) | Stock incentive plans
Business Acquisition [Line Items]
Vesting rate upon anniversaries		33.33%
First anniversary | Restricted Stock Units (RSUs) | Stock incentive plans | Singular Bio
Business Acquisition [Line Items]
Vesting rate upon anniversaries	33.33%	33.33%
Second anniversary | Restricted Stock Units (RSUs) | Stock incentive plans
Business Acquisition [Line Items]
Vesting rate upon anniversaries		33.33%
Second anniversary | Restricted Stock Units (RSUs) | Stock incentive plans | Singular Bio
Business Acquisition [Line Items]
Vesting rate upon anniversaries	33.33%	33.33%
Third anniversary | Restricted Stock Units (RSUs) | Stock incentive plans
Business Acquisition [Line Items]
Vesting rate upon anniversaries		33.33%
Third anniversary | Restricted Stock Units (RSUs) | Stock incentive plans | Singular Bio
Business Acquisition [Line Items]
Vesting rate upon anniversaries	33.33%	33.33%

Business combinations - Jungla

Business combinations - Jungla (Details) - Jungla - USD ($) shares in Millions, $ in Millions	1 Months Ended	3 Months Ended
	Jul. 31, 2019	Mar. 31, 2020
Business Acquisition [Line Items]
Percentage of diluted interest acquired	100.00%
Business combination, total purchase consideration	$ 59
Common stock transferred	$ 44.9
Hold-back consideration - common stock		$ 2.7
Indemnification obligations
Business Acquisition [Line Items]
Business acquisition common stock issued (in shares)	0.2	0.2
Ongoing development post-close milestones
Business Acquisition [Line Items]
Contingent consideration	$ 10.7
Business acquisition, expected milestone duration	2 years

Business combinations - Clear G

Business combinations - Clear Genetics (Details) - Clear Genetics - USD ($) shares in Millions, $ in Millions	1 Months Ended	3 Months Ended
	Nov. 30, 2019	Mar. 31, 2020
Business Acquisition [Line Items]
Percentage of diluted interest acquired	100.00%
Business combination, total purchase consideration	$ 50.1
Hold-back consideration - common stock		$ 5.7
Indemnification obligations
Business Acquisition [Line Items]
Hold-back consideration - cash	$ 0.2
Business acquisition common stock issued (in shares)	0.4	0.4

Business combinations - Diploid

Business combinations - Diploid (Details) - USD ($) $ in Thousands, shares in Millions	1 Months Ended	3 Months Ended	12 Months Ended
	Mar. 31, 2020	Mar. 31, 2020	Dec. 31, 2019
Business Acquisition [Line Items]
Useful life		8 years 10 months 24 days	8 years 10 months 24 days
Goodwill	$ 177,432	$ 177,432	$ 126,777
Diploid
Business Acquisition [Line Items]
Business combination, total purchase consideration	$ 82,314
Useful life	9 years
Hold-back consideration - common stock	$ 7,538
Contingent consideration	5,800	5,800
Goodwill	50,655	50,655
Shares of common stock subject to outstanding RSUs | Stock incentive plans | Diploid
Business Acquisition [Line Items]
Business acquisition, value of units granted	$ 5,000	$ 5,000
Indemnification obligations | Diploid
Business Acquisition [Line Items]
Business acquisition common stock issued (in shares)	0.4

Business combinations - Summary

Business combinations - Summary of the purchase price and post-combination expense (Details) - Diploid $ in Thousands	1 Months Ended
	Mar. 31, 2020USD ($)
Purchase Price
Cash transferred	$ 32,323
Hold-back consideration - common stock	7,538
Common stock transferred	42,453
Total	$ 82,314

Business combinations - Summa_2

Business combinations - Summary of fair values of assets acquired and liabilities assumed (Details) - USD ($) $ in Thousands	Mar. 31, 2020	Dec. 31, 2019
Business Acquisition [Line Items]
Goodwill	$ 177,432	$ 126,777
Diploid
Business Acquisition [Line Items]
Cash	124
Accounts receivable	26
In-process research and development	41,789
Total identifiable assets acquired	41,939
Accounts payable	(30)
Deferred tax liability	(10,250)
Net identifiable assets acquired	31,659
Goodwill	50,655
Total purchase price	$ 82,314

Goodwill and intangible asset_2

Goodwill and intangible assets - Summary of goodwill (Details) $ in Thousands	3 Months Ended
	Mar. 31, 2020USD ($)
Goodwill [Line Items]
Beginning Balance	$ 126,777
Ending Balance	177,432
Diploid
Goodwill [Line Items]
Goodwill acquired	50,655
Ending Balance	$ 50,655

Goodwill and intangible asset_3

Goodwill and intangible assets - Schedule of intangible assets (Details) - USD ($) $ in Thousands	3 Months Ended	12 Months Ended
	Mar. 31, 2020	Dec. 31, 2019
Finite-Lived Intangible Assets [Line Items]
Accumulated Amortization	$ (18,163)	$ (14,577)
Net, finite intangible assets	$ 133,390
Weighted-Average Useful Life (in Years)	8 years 10 months 24 days	8 years 10 months 24 days
Cost	$ 181,541	$ 139,752
Net	163,378	125,175
Customer relationships
Finite-Lived Intangible Assets [Line Items]
Cost, finite intangible	23,763	23,763
Accumulated Amortization	(5,841)	(5,141)
Net, finite intangible assets	$ 17,922	$ 18,622
Weighted-Average Useful Life (in Years)	10 years	10 years
Developed technology
Finite-Lived Intangible Assets [Line Items]
Cost, finite intangible	$ 126,185	$ 84,396
Accumulated Amortization	(11,291)	(8,476)
Net, finite intangible assets	$ 114,894	$ 75,920
Weighted-Average Useful Life (in Years)	8 years 8 months 12 days	8 years 7 months 6 days
Non-compete agreement
Finite-Lived Intangible Assets [Line Items]
Cost, finite intangible	$ 286	$ 286
Accumulated Amortization	(186)	(172)
Net, finite intangible assets	$ 100	$ 114
Weighted-Average Useful Life (in Years)	5 years	5 years
Trade name
Finite-Lived Intangible Assets [Line Items]
Cost, finite intangible	$ 576	$ 576
Accumulated Amortization	(519)	(480)
Net, finite intangible assets	$ 57	$ 96
Weighted-Average Useful Life (in Years)	2 years 8 months 12 days	2 years 8 months 12 days
Patent licensing agreement
Finite-Lived Intangible Assets [Line Items]
Cost, finite intangible	$ 496	$ 496
Accumulated Amortization	(79)	(70)
Net, finite intangible assets	$ 417	$ 426
Weighted-Average Useful Life (in Years)	15 years	15 years
Favorable leases
Finite-Lived Intangible Assets [Line Items]
Cost, finite intangible	$ 247	$ 247
Accumulated Amortization	(247)	(238)
Net, finite intangible assets	$ 0	$ 9
Weighted-Average Useful Life (in Years)	2 years 2 months 12 days	2 years 2 months 12 days
In-process research and development
Finite-Lived Intangible Assets [Line Items]
In-process research and development	$ 29,988	$ 29,988

Goodwill and intangible asset_4

Goodwill and intangible assets - Additional information (Details) - USD ($) $ in Millions	3 Months Ended
	Mar. 31, 2020	Mar. 31, 2019
Goodwill and Intangible Assets Disclosure [Abstract]
Amortization expense	$ 3.6	$ 1.3

Goodwill and intangible asset_5

Goodwill and intangible assets - Summary of estimated future amortization expense of intangible assets with finite lives (Details) $ in Thousands	Mar. 31, 2020USD ($)
Goodwill and Intangible Assets Disclosure [Abstract]
2020 (remainder of year)	$ 13,568
2021	18,426
2022	16,721
2023	15,708
2024	15,430
Thereafter	53,537
Net, finite intangible assets	$ 133,390

Balance sheet components - Sche

Balance sheet components - Schedule of property and equipment (Details) - USD ($) $ in Thousands	Mar. 31, 2020	Dec. 31, 2019
Property and equipment
Total property and equipment, gross	$ 69,066	$ 63,882
Accumulated depreciation and amortization	(27,981)	(26,135)
Total property and equipment, net	41,085	37,747
Leasehold improvements
Property and equipment
Total property and equipment, gross	21,422	18,352
Laboratory equipment
Property and equipment
Total property and equipment, gross	26,983	24,873
Computer equipment
Property and equipment
Total property and equipment, gross	6,476	5,995
Software
Property and equipment
Total property and equipment, gross	2,611	2,611
Furniture and fixtures
Property and equipment
Total property and equipment, gross	1,277	1,198
Automobiles
Property and equipment
Total property and equipment, gross	58	58
Construction-in-progress
Property and equipment
Total property and equipment, gross	$ 10,239	$ 10,795

Balance sheet components - Addi

Balance sheet components - Additional information (Details) - USD ($) $ in Millions	3 Months Ended
	Mar. 31, 2020	Mar. 31, 2019
Balance Sheet Related Disclosures [Abstract]
Depreciation	$ 2	$ 1.6

Balance sheet components - Sc_2

Balance sheet components - Schedule of accrued liabilities (Details) - USD ($) $ in Thousands	Mar. 31, 2020	Dec. 31, 2019
Balance Sheet Related Disclosures [Abstract]
Accrued compensation and related expenses	$ 18,927	$ 16,440
Compensation and other liabilities associated with business combinations	55,789	30,560
Deferred revenue	1,460	1,429
Other	12,617	16,385
Total accrued liabilities	$ 88,793	$ 64,814

Fair value measurements - Finan

Fair value measurements - Financial instruments at fair value on a recurring basis (Details) - USD ($) $ in Thousands	Mar. 31, 2020	Dec. 31, 2019
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]
Amortized Cost	$ 235,747	$ 383,625
Unrealized Gains	1,294	6
Unrealized Losses		(15)
Financial assets:	237,041	383,616
Cash equivalents	26,310	136,997
Restricted cash	6,343	6,183
Marketable securities	204,388	240,436
Accrued liabilities	88,793	64,814
Other long-term liabilities	17,062	8,000
Recurring basis
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]
Total financial assets	237,041	383,616
Total financial liabilities	25,562	11,300
Recurring basis | Level 1
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]
Total financial assets	171,747	190,008
Recurring basis | Level 2
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]
Total financial assets	65,294	193,608
Recurring basis | Level 3
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]
Total financial liabilities	25,562	11,300
Money market funds
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]
Amortized Cost	32,653	39,396
Money market funds | Recurring basis
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]
Financial assets:	32,653	39,396
Money market funds | Recurring basis | Level 1
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]
Financial assets:	32,653	39,396
Certificates of deposit
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]
Amortized Cost	300	300
Certificates of deposit | Recurring basis
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]
Financial assets:	300	300
Certificates of deposit | Recurring basis | Level 2
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]
Financial assets:	300	300
U.S. treasury notes
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]
Amortized Cost	137,937	150,627
Unrealized Gains	1,157
Unrealized Losses		(15)
U.S. treasury notes | Recurring basis
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]
Financial assets:	139,094	150,612
U.S. treasury notes | Recurring basis | Level 1
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]
Financial assets:	139,094	150,612
U.S. government agency securities
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]
Amortized Cost	64,857	193,302
Unrealized Gains	137	6
U.S. government agency securities | Recurring basis
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]
Financial assets:	64,994	193,308
U.S. government agency securities | Recurring basis | Level 2
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]
Financial assets:	64,994	193,308
Stock payable liability | Recurring basis
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]
Total financial liabilities	14,362
Stock payable liability | Recurring basis | Level 3
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]
Total financial liabilities	14,362
Contingent consideration
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]
Accrued liabilities	8,500	3,300
Other long-term liabilities	17,062	8,000
Contingent consideration | Recurring basis
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]
Total financial liabilities	11,200	11,300
Contingent consideration | Recurring basis | Level 3
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]
Total financial liabilities	$ 11,200	$ 11,300

Fair value measurements - Addit

Fair value measurements - Additional information (Details)	3 Months Ended
	Mar. 31, 2020USD ($)security	Mar. 31, 2019USD ($)	Dec. 31, 2019USD ($)	Jul. 31, 2019USD ($)
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]
Transfers of assets and liabilities between Level 1, Level 2 and Level 3	$ 0		$ 0
Fair value of investments with unrealized losses	$ 0
Number of securities that are in continuous unrealized loss position for more than one year | security	0
Other than temporary impairment losses	$ 0
Interest income	1,000,000	$ 600,000
Change in fair value	(3,400,000)
Level 3 | Contingent consideration | Ongoing development post-close milestones | Jungla
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]
Contingent obligation, fair value	$ 11,200,000			$ 10,700,000

Commitments and contingencies -

Commitments and contingencies - Operating lease - Additional information (Details) - USD ($) $ in Millions	3 Months Ended
	Mar. 31, 2020	Dec. 31, 2015
Lessor, Lease, Description [Line Items]
Weighted-average remaining lease term	6 years 3 months 18 days
Weighted-average discount rate	11.60%
Operating lease, cash payments	$ 2.7
New Leases | Office Facility In San Francisco
Lessor, Lease, Description [Line Items]
Additional term of lease		10 years
Lease term		10 years
Security Deposit		$ 4.6

Commitments and contingencies_2

Commitments and contingencies - Components of lease cost (Details) - USD ($) $ in Thousands	3 Months Ended
	Mar. 31, 2020	Mar. 31, 2019
Commitments and Contingencies Disclosure [Abstract]
Operating lease costs	$ 2,615	$ 2,517
Sublease income	0	(43)
Total operating lease costs	2,615	2,474
Finance lease costs	484	420
Total lease costs	$ 3,099	$ 2,894

Commitments and contingencies_3

Commitments and contingencies - Schedule of future minimum payments under operating leases (Details) - USD ($) $ in Thousands	Mar. 31, 2020	Dec. 31, 2019
Future minimum lease payments under operating leases
2020 (remainder of year)	$ 7,770
2021	10,671
2022	10,631
2023	10,424
2024	10,560
Thereafter	18,459
Future non-cancelable minimum operating lease payments	68,515
Less: imputed interest	(20,623)
Total operating lease liabilities	47,892
Less: current portion	(5,125)	$ (4,870)
Operating lease obligations, net of current portion	$ 42,767	$ 42,191

Commitments and contingencies_4

Commitments and contingencies - Finance lease - Additional information (Details) - USD ($) $ in Millions	3 Months Ended
	Mar. 31, 2020	Mar. 31, 2019	Dec. 31, 2019
Commitments and Contingencies Disclosure [Abstract]
Lease term	3 years
Weighted-average remaining lease term	2 years
Weighted-average discount rate	5.70%
Finance Lease, Right-of-Use Asset	$ 5.1		$ 5.6
Finance lease, cash payments	$ 0.7	$ 0.5

Commitments and contingencies_5

Commitments and contingencies - Schedule of future minimum lease payments under finance leases (Details) - USD ($) $ in Thousands	Mar. 31, 2020	Dec. 31, 2019
Future payments under the finance lease
2020 (remainder of year)	$ 1,306
2021	611
2022	611
Total finance lease obligations	2,528
Less: interest	(139)
Present value of net minimum finance lease payments	2,389
Less: current portion	(1,370)	$ (1,855)
Finance lease obligations, net of current portion	$ 1,019	$ 1,155

Commitments and contingencies_6

Commitments and contingencies - Debt financing - Additional information (Details) - USD ($)	1 Months Ended		3 Months Ended
	Sep. 30, 2019	Nov. 30, 2018	Mar. 31, 2020	Mar. 31, 2019
Note Purchase Agreement
Long-term Purchase Commitment [Line Items]
Maximum borrowing capacity		$ 200,000,000
Maturity term		7 years
Repayment of debt	$ 85,700,000
Repayment of principal	75,000,000
Repayment of accrued interest	2,400,000
Payments of debt extinguishment costs	$ 8,900,000
Initial sale of notes | Note Purchase Agreement
Long-term Purchase Commitment [Line Items]
Maximum borrowing capacity		$ 75,000,000
Proceeds from notes sold		10,300,000
Loan and Security Agreement | Secured Debt
Long-term Purchase Commitment [Line Items]
Repayment of term loan		$ 64,700,000
Interest expense			$ 0	$ 2,000,000

Commitments and contingencies_7

Commitments and contingencies - Convertible Senior Notes - Additional information (Details)	1 Months Ended	3 Months Ended
	Sep. 30, 2019USD ($)Trading_day$ / sharesshares	Mar. 31, 2020USD ($)
Convertible debt | Convertible Senior Notes
Debt Instrument [Line Items]
Aggregate principal amount | $		$ 350,000,000
Stated interest rate		2.00%
Conversion rate (in shares) | shares	33.6293
Conversion rate, principal | $	$ 1,000
Conversion price (in dollars per share) | $ / shares	$ 29.74
Redemption price, percent of principle	100.00%
Number of trading days | Trading_day	20
Number of consecutive trading days | Trading_day	30
Threshold percentage of stock price trigger	130.00%
Number of trading days immediately after five consecutive trading days | Trading_day	5
Threshold percentage of stock price trigger, maximum	98.00%
Redemption period, number of trading days | Trading_day	30
Interest expense | $		$ 5,400,000
Level 2
Debt Instrument [Line Items]
Convertible debt fair value | $		$ 310,800,000

Commitments and contingencies_8

Commitments and contingencies - Components of debt (Details) - Convertible debt - Convertible Senior Notes $ in Thousands	Mar. 31, 2020USD ($)
Debt Instrument [Line Items]
Outstanding principal	$ 350,000
Unamortized debt discount and issuance costs	(77,613)
Net carrying amount, liability component	$ 272,387

Commitments and contingencies_9

Commitments and contingencies - Other commitments - Additional information (Details) $ in Millions	Mar. 31, 2020USD ($)
Service Agreements and Laboratory Supplies
Other Commitments [Line Items]
Noncancelable unconditional purchase commitments	$ 9.2

Stockholders' equity - Schedule

Stockholders' equity - Schedule of convertible preferred and common stock (Details) - shares shares in Thousands	3 Months Ended
	Mar. 31, 2020	Mar. 31, 2019
Convertible preferred stock:
Increase (Decrease) in Stockholders' Equity [Roll Forward]
Shares outstanding, beginning of period	125	3,459
Shares converted		3,334
Shares outstanding, end of period	125	125
Common stock:
Increase (Decrease) in Stockholders' Equity [Roll Forward]
Shares outstanding, beginning of period	98,796	75,481
Shares converted		3,334
Common stock issued in connection with public offering (in shares)		10,350
Common stock issued on exercise of stock options, net (in shares)	178	260
Common stock issued pursuant to vesting of RSUs (in shares)	426	121
Common stock issued pursuant to exercises of warrants (in shares)	142	15
Common stock issued pursuant to business combinations (in shares)	2,378	40
Shares outstanding, end of period	101,920	89,601

Stock incentive plans - Additio

Stock incentive plans - Additional information (Details) - USD ($) $ in Millions	1 Months Ended			3 Months Ended
	Jul. 31, 2019	Jun. 30, 2019	Jan. 31, 2015	Mar. 31, 2020	Mar. 31, 2019
Restricted Stock Units (RSUs)
Stock incentive plan
Vested stock units awarded (in shares)				426,000
Stock incentive plans
Stock incentive plan
Vesting period				4 years
Stock incentive plans | Restricted Stock Units (RSUs)
Stock incentive plan
Vesting period				3 years
Stock incentive plans | Stock options
Stock incentive plan
Vesting period				4 years
Vesting rate upon anniversaries				25.00%
Monthly vesting rate thereafter				2.08%
Total grant date fair value of options to purchase common stock vested				$ 0.7	$ 1.1
Exercised, aggregate intrinsic value				$ 2.3	$ 3.3
Stock incentive plans | First anniversary | Restricted Stock Units (RSUs)
Stock incentive plan
Vesting rate upon anniversaries				33.33%
Stock incentive plans | Second anniversary | Restricted Stock Units (RSUs)
Stock incentive plan
Vesting rate upon anniversaries				33.33%
Stock incentive plans | Third anniversary | Restricted Stock Units (RSUs)
Stock incentive plan
Vesting rate upon anniversaries				33.33%
2019 Incentive Compensation Plan | Performance Restricted Stock Units (PRSUs)
Stock incentive plan
Vesting period	2 years
Vested stock units awarded (in shares)				800,000
2015 Employee Stock Purchase Plan
Stock incentive plan
Purchase price of common stock of the lesser of fair market value on the purchase date or the last trading day preceding the offering date			85.00%
Cash received from payroll deductions				$ 3.4
Shares reserved for future issuance				1,600,000
Minimum | 2010 Plan
Stock incentive plan
Employees holding voting rights of all classes of stock				10.00%
Exercise price of options on common stock				110.00%
Maximum | 2010 Plan
Stock incentive plan
Term of options granted				10 years
Singular Bio | Stock incentive plans | Performance Restricted Stock Units (PRSUs)
Stock incentive plan
Vesting period		12 months		18 months
Vested stock units awarded (in shares)				0
Singular Bio | Stock incentive plans | First anniversary | Restricted Stock Units (RSUs)
Stock incentive plan
Vesting rate upon anniversaries		33.33%		33.33%
Singular Bio | Stock incentive plans | Second anniversary | Restricted Stock Units (RSUs)
Stock incentive plan
Vesting rate upon anniversaries		33.33%		33.33%
Singular Bio | Stock incentive plans | Third anniversary | Restricted Stock Units (RSUs)
Stock incentive plan
Vesting rate upon anniversaries		33.33%		33.33%

Stock incentive plans - Schedul

Stock incentive plans - Schedule of activity under the plans (Details) - USD ($) $ / shares in Units, shares in Thousands, $ in Thousands	3 Months Ended	12 Months Ended
	Mar. 31, 2020	Dec. 31, 2019
Time-based RSUs and PRSUs
Activity under the plan
RSUs granted (in shares)	(1,005)
Stock incentive plans | Stock options
Activity under the plan
Shares available for grant, beginning balance (in shares)	5,444
Stock options outstanding, beginning balance (in shares)	3,542
Additional shares reserved (in shares)	4,552
Options exercised (in shares)	(178)
Shares available for grant, ending balance (in shares)	9,005	5,444
Stock options outstanding, ending balance (in shares)	3,364	3,542
Weighted-Average Exercise Price
Balance at the beginning of the period (in dollars per share)	$ 9.49
Options exercised (in dollars per share)	6.44
Balance at the end of the period (in dollars per share)	$ 9.66	$ 9.49
Additional information
Exercisable, number of shares	2,954
Exercisable, weighted-average exercise price (in dollars per share)	$ 8.98
Weighted-average remaining contractual life	5 years 10 months 24 days	6 years 1 month 6 days
Aggregate Intrinsic Value	$ 15,430	$ 24,966
Exercisable, weighted-average remaining contractual life	5 years 7 months 6 days
Exercisable, aggregate intrinsic value	$ 14,187
Vested and expected to vest
Number of shares	3,311
Weighted-average exercise price (in dollars per share)	$ 9.56
Weighted-average remaining contractual life	5 years 10 months 24 days
Aggregate intrinsic value	$ 15,290
Stock incentive plans | Time-based RSUs and PRSUs
Activity under the plan
RSUs granted (in shares)	(1,223)
RSUs cancelled (in shares)	232

Stock incentive plans - Summary

Stock incentive plans - Summary of RSU activity (Details) shares in Thousands	3 Months Ended
	Mar. 31, 2020$ / sharesshares
Restricted Stock Units (RSUs)
Number of Shares
Balance at the beginning of the period (in shares) | shares	8,885
RSUs granted (in shares) | shares	218
Vested stock units awarded (in shares) | shares	(426)
RSUs cancelled (in shares) | shares	(232)
Balance at the end of the period (in shares) | shares	9,450
Weighted- Average Grant Date Fair Value Per Share
Balance at the beginning of the period (in dollars per share) | $ / shares	$ 15.17
RSUs granted (in dollars per share) | $ / shares	17.89
RSUs vested (in dollars per share) | $ / shares	18
RSUs cancelled (in dollars per share) | $ / shares	20.27
Balance at the end of the period (in dollars per share) | $ / shares	$ 14.82
Time-based RSUs and PRSUs
Number of Shares
RSUs granted (in shares) | shares	1,005
Weighted- Average Grant Date Fair Value Per Share
RSUs granted (in dollars per share) | $ / shares	$ 13.67

Stock incentive plans - Summa_2

Stock incentive plans - Summary of stock based compensation expense (Details) - USD ($) $ in Thousands	3 Months Ended
	Mar. 31, 2020	Mar. 31, 2019
Stock-based compensation
Total stock-based compensation expense	$ 29,278	$ 5,223
Cost of revenue
Stock-based compensation
Total stock-based compensation expense	861	651
Research and development
Stock-based compensation
Total stock-based compensation expense	22,204	1,805
Selling and marketing
Stock-based compensation
Total stock-based compensation expense	1,823	1,243
General and administrative
Stock-based compensation
Total stock-based compensation expense	$ 4,390	$ 1,524

Net loss per share - Schedule o

Net loss per share - Schedule of earnings per share, basic and diluted (Details) - USD ($) $ / shares in Units, shares in Thousands, $ in Thousands	3 Months Ended
	Mar. 31, 2020	Mar. 31, 2019
Earnings Per Share [Abstract]
Net loss	$ (98,527)	$ (37,677)
Shares used in computing net loss per share, basic and diluted	99,632	79,369
Net loss per share, basic and diluted (in dollars per share)	$ (0.99)	$ (0.47)

Net loss per share - Schedule_2

Net loss per share - Schedule of antidilutive securities excluded from computation of earnings per share (Details) - shares shares in Thousands	3 Months Ended
	Mar. 31, 2020	Mar. 31, 2019
Antidilutive shares excluded from diluted net loss per share
Total shares of common stock equivalents (in shares)	25,921	11,176
Shares of common stock subject to outstanding options
Antidilutive shares excluded from diluted net loss per share
Total shares of common stock equivalents (in shares)	3,478	3,759
Shares of common stock subject to outstanding warrants
Antidilutive shares excluded from diluted net loss per share
Total shares of common stock equivalents (in shares)	489	609
Shares of common stock subject to outstanding RSUs
Antidilutive shares excluded from diluted net loss per share
Total shares of common stock equivalents (in shares)	5,703	4,130
Shares of common stock subject to outstanding PRSUs
Antidilutive shares excluded from diluted net loss per share
Total shares of common stock equivalents (in shares)	3,988	0
Shares of common stock pursuant to ESPP
Antidilutive shares excluded from diluted net loss per share
Total shares of common stock equivalents (in shares)	368	213
Shares of common stock underlying Series A convertible preferred stock
Antidilutive shares excluded from diluted net loss per share
Total shares of common stock equivalents (in shares)	125	2,465
Shares of common stock subject to convertible senior notes exercise
Antidilutive shares excluded from diluted net loss per share
Total shares of common stock equivalents (in shares)	11,770	0

Geographic information - Schedu

Geographic information - Schedule of revenue by country (Details) - USD ($) $ in Thousands	3 Months Ended
	Mar. 31, 2020	Mar. 31, 2019
Geographic information
Total revenue	$ 64,248	$ 40,553
United States
Geographic information
Total revenue	59,806	37,645
Canada
Geographic information
Total revenue	1,219	965
Rest of world
Geographic information
Total revenue	$ 3,223	$ 1,943

Subsequent events (Details)

Subsequent events (Details) - USD ($) $ / shares in Units, $ in Thousands	1 Months Ended	3 Months Ended
	Apr. 30, 2020	Mar. 31, 2020	Mar. 31, 2019
Subsequent Event [Line Items]
Proceeds from issuance of common stock		$ 1,172	$ 2,107
Subsequent event
Subsequent Event [Line Items]
Number of shares sold in underwritten public offering	20,400,000
Shares issued price per share (in dollars per share)	$ 9
Proceeds from issuance of common stock	$ 184,000
Net proceeds from issuance of common stock	$ 173,000
YouScript | Subsequent event
Subsequent Event [Line Items]
Percentage of diluted interest acquired	100.00%
Business acquisition common stock issued (in shares)	1,800,000
Cash transferred	$ 23,600
Genelex | Subsequent event
Subsequent Event [Line Items]
Percentage of diluted interest acquired	100.00%
Business acquisition common stock issued (in shares)	800,000
Business acquisition, expected milestone duration	4 years
Indemnification obligations | YouScript | Subsequent event
Subsequent Event [Line Items]
Business acquisition common stock issued (in shares)	500,000
Hold-back consideration - cash	$ 1,400
Indemnification obligations | Genelex | Subsequent event
Subsequent Event [Line Items]
Business acquisition common stock issued (in shares)	100,000